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The rapid growing number of patients diagnosed with a neurodegenerative disease and more 
particularly with Alzheimer’s disease (AD) has stimulated intensive research in determining and 
understanding biological phenomena causing such devastating diseases and hence allowing for 
the elaboration of adapted therapeutic treatments. These diseases are also commonly called 
“conformational” diseases because they result from the misfolding of a protein leading to the 
formation of self-associated β-sheets, which in turn give rise to the formation of oligomers, 
protofibrils as well as insoluble fibrils characterizing the plaques found in the brain of affected 
patients. Consequently, the investigation of such proteins, in particular of Amyloid β (Aβ) in the 
case of AD, is a limited and difficult task to achieve, which often leads to contradictory results. 
To overcome these difficulties and to be able to study the key steps of conformational transitions 
and misfolding of such peptides and proteins, our research group has developed a new tool, 
called switch-peptides, enabling to block (Soff state) and trigger (Son state) peptide folding at will 
(Figure). 
 
 
The introduction of a switch element S built from Ser, Thr or Cys residues disrupts the regular 
polypeptide chain by the insertion of an ester and a flexible C-C bond resulting in a 
conformational disconnection of P1 and P2 (Figure), i.e. in an unordered (random coil), non-
folded conformation. Each S element is protected by a protecting group Y (Soff state) that can be 
cleaved independently by adding a base, an enzyme or by light, depending on the chemical 
nature of Y. The cleavage of the different protecting groups Y triggers a spontaneous O to N 
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acyl migration, re-establishing the regular amide backbone of the peptide chain, hence enabling 
the peptide to fold “in statu nascendi” and to adopt a well-defined secondary structure. 
The present thesis explores the potential of this novel concept for the example of conformational 
transitions relevant in amyloid β misfolding.  
In the first part we investigate the chemical stability of the S element in aqueous media, exposing 
a number of switch-peptides to various experimental conditions. Most notably, the ester bond 
proved to be stable at acidic as well as physiological conditions for several hours, opening a 
broad range of biological applications. 
The second part of the work is dedicated to the study of conformational transitions of switch-
peptides derived from Aβ(1-42). By incorporating one or several switch elements disposing 
orthogonal protecting groups Y, the impact of different fragments of the peptide as nucleation 
site for the process of β-sheet formation, self-assembly and aggregation has been revealed as 
monitored by CD, TEM studies and ThT (pathway B, Figure). For the first time, the orthogonal 
triggering of the two switch elements, i.e. S26 and S37 allowed to delineate the important role of 
the C-terminal part of Aβ in the early step of misfolding. 
Subsequently, one of the nucleation sites for aggregation, i.e. segment Aβ(14-24) was excised 
from the native sequence and transformed to a switch-peptide applying the host-guest technique. 
Detailed CD studies were applied for investigating conformational transitions of type random-
coil (Soff) to β-sheet structure (Son), serving as proof of concept for the use of Aβ-derived 
nucleation sites as guest sequence in combination with β-sheet promoting host peptides for the 
screening of potential inhibitors of fibril formation as early molecular event in the context of 
AD. 
This has been demonstrated in applying the elaborated host-guest peptides to evaluate the β-
sheet breaking potential of pseudo-proline (ψPro)-containing switch-peptides derived from Aβ 
(pathway C, Figure). Preliminary results indicate that the in situ formation of kink-
conformations may exert a β-sheet destabilizing effect, confirming previous observations from  
the Soto group.  
Finally, the use of switch-peptides as β-sheet and fibril breaking molecules by in situ α-helix 
nucleation (pathway A, Figure) has been explored. To this end, the potentially β-sheet forming 
segment Aβ(14-24) was linked via S element to a helix nucleating peptidomimetic (“N-Cap”). In 
the Soff state (pH ≤ 4), CD and TEM studies point to the onset of a β-sheet, fibril forming 
structure. In triggering O,N-acyl migration (pH ≈ 7), a so far unprecedented transition of type β-
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sheet to α-helix is observed, paralleled by a drastic increase in solubility and a complete 
disappearance of fibrils. 
The reversibility of β-sheet and fibril formation by α-helix nucleation in situ represents a most 
interesting observation and deserves further exploration as potential tool in the study of folding 
processes. 
In conclusion, the concept of “switch-peptides” has been successfully applied to biologically 
relevant molecular events of utmost therapeutical interest. 
 
Keywords: Amyloid β-derived switch-peptides; multiple O,N-acyl migration; conformational 
transitions; fibril disruption; neurodegenerative diseases; reversal of β-sheet formation. 
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Résumé   
 
 
 
Le nombre croissant de patients atteints de maladies neurodégénératives et plus particulièrement 
de la maladie d’Alzheimer a stimulé la recherche ayant pour but de déterminer et comprendre les 
phénomènes biologiques causant ces maladies dévastatrices afin de permettre l’élaboration de 
traitements thérapeutiques adaptés. Ces maladies sont aussi communément appelées maladies 
“conformationnelles” car elles résultent principalement du mauvais repliement d’une protéine 
conduisant à la formation de feuillets β s’associant entre eux pour donner naissance à des 
oligomères, des protofibrilles ainsi que des fibrilles insolubles qui caractérisent les plaques 
retrouvées dans le cerveau des patients atteints. Par conséquent, l’étude de ces protéines, plus 
particulièrement de l’Amyloide β, est limitée et difficile, donnant souvent lieu à des résultats 
contradictoires. Afin de contourner ces difficultés pour pouvoir plus facilement étudier les étapes 
clés du changement de conformation et du repliement incorrect de l’Aβ, notre groupe de 
recherche a développé un nouvel outil, appelé les « switch-peptides », permettant de bloquer 
(état Soff) puis de déclencher (état Son) le repliement du peptide à souhait (Figure).  
 
 
 
L’introduction d’un élément switch S construit à partir des résidues Ser, Thr ou Cys interrompt 
la chaine polypepidique par l’insertion d’une liaision ester et d’une liaison C-C flexible resultant 
dans une deconnection conformationnelle de P1 et P2 (Figure), c-à-d dans une conformation 
désordonnée de type pelote statistique. Les éléments S sont protégés par des groupes protecteurs 
Y (état Soff) pouvant être clivés de manière indépendante par l’ajout d’une base, d’une enzyme 
ou par la lumière, dépendant de la nature chimique de Y. Le clivage de Y déclenche une 
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migration acylique spontanée qui rétablit la liaison amide et la chaîne peptidique, ce qui permet 
au peptide de se replier « in statu nascendi » et d’adopter une structure secondaire définie. 
Le travail décrit dans cette thèse explore le potentiel de ce nouveau concept pour l’exemple des 
transitions conformationnelles de grande importance dans le repliement incorrect de l’amyloide 
β (Αβ).  
Dans un premier temps, nous avons étudié la stabilité de l’élément S en milieu aqueux, exposant 
plusieurs « switch-peptides » à différentes conditions expérimentales. Nous avons notamment 
démontré que dans des conditions acides et physiologiques, la liaison ester reste stable pour 
plusieurs heures, donnant accès à un large éventail d’applications biologiques. 
Nous nous sommes ensuite consacrés à l’étude des changements conformationnels de « switch-
peptides » dérivés de l’amyloide β 1-42. Par l’incorporation d’un ou plusieurs éléments switch 
disposants de groupes protecteurs orthogonaux Y, l’impact de différents fragments du peptide 
comme site de nucléation dans le processus de formation des feuillets β, de l’auto-assemblage et 
l’aggregation (voie B, Figure) a été révélé grâce à l’utilisation de plusieurs techniques 
complémentaires telles que CD, TEM et ThT. Pour la première fois, le déclenchement 
orthogonal de deux éléments switch, c-à-d S26 et S37 a permit de déterminer le rôle majeur de la 
partie C-terminale de l’Aβ dans les premières étapes du repliement incorrect du peptide. 
Ensuite, un des sites de nucléation de l’aggrégation, le segment Aβ(14-24) fut excisé de la 
séquence native et transformé en un « switch-peptide » appliquant la technique host-guest. Des 
études détailées par CD furent utilisées afin d’examiner les transitions conformationnelles de 
type pelote statistique (Soff) à feuillet β (Son), servant de preuve du concept dans l’utilisation de 
sites de nucléation dérivés de l’Aβ comme séquence guest en combinaison avec des peptides 
host promoteurs de feuillets β pour le screening d’inhibiteurs potentiels de la formation des 
fibrilles, événement moléculaire majeur survenant tôt dans le contexte de la maladie 
d’Alhzeimer. 
Ceci fut démontré en appliquant les peptides host-guest élaborés à l’évaluation de « switch-
peptides » dérivés de l’amyloid β comprenant une pseudo-proline (ψPro) comme potentiels 
briseurs de feuillets β (voie C, Figure). Les résultats préliminaires indiquent que la formation in 
situ de conformations en coude peut exercer un effet déstabilisant sur les feuillets β, confirmant 
ainsi de précédentes observations faites par C. Soto et al. 
Enfin, l’utilisation de « switch-peptides » comme molécules capables de briser feuillets β et 
fibrilles par la nucléation in situ d’une helice α (voie A, Figure) a été explorée. A cette fin, le 
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segment Aβ(14-24) formant des feuillets β a été lié via un élément S à un peptidomimétique 
nucléateur d’hélices (« N-Cap »). À l’état Soff (pH ≤ 4), les études CD et TEM pointent vers le 
commencement d’une structure de type feuillet β formant des fibrilles. Par le déclenchement de 
la migration acylique (pH ≈ 7), une transition de type feuillet β à helice α jamais observée 
jusqu’à présent a pu être démontrée. Parallèlement, une augmentation extrême de la solubilité et 
la disparition complète des fibrilles furent observées.  
La réversibilité  de la formation des feuillets β et des fibrilles par nucléation in situ d’hélice α 
représente une observation extrêmement importante et mérite une exploration plus approfondie 
comme outil potentiel dans l’étude des processus du repliement des protéines. 
En conclusion, le concept des « switch-peptides » fut appliqué avec succès dans l’étude des 
événements biologiques moléculaires d’intérêt thérapeutique majeur. 
 
Mots clés: “switch-peptides” dérivés de l’amyloide β ; multiple O,N-acyl migration ; transitions 
conformationnelles ; déstabilisation de fibrilles ; maladies neurodégénératives ; réversibilité de la 
formation de feuillets β. 
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Aβ Amyloid β 
Abs Absorbance 
Ac Acetyl 
AcN Acetonitrile 
AcOEt Ethyl acetate 
AD Alzheimer’s disease 
APP Amyloid precursor protein 
Boc tert-Butyloxycarbonyl 
Boc2O Di-tert-butyl dicarbonate 
Bzl Benzoyl 
CD Circular dichroism 
CDCl3 Deuterochloroform 
DCC N,N’-Dicyclohexylcarbodiimide 
DIC N,N’-Diisopropylcarbodiimide 
DCM dichloromethane 
DEA diethylamine 
DIPEA N,N-Ethyldiisopropylamine 
DPPIV Dipeptidyl aminopeptidase IV 
DMAP Dimethylaminopyridine 
DMF Dimethylformamide 
DMSO Dimethylsulfoxide 
D2O Deuterium oxyde 
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EDCI 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide 
EM Electron microscopy 
ESI-MS Electrospray Ionisation Mass Spectroscopy 
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EtOH Ethanol 
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PBS Phosphate buffer solution 
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SPPS Solid phase peptide synthesis 
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Chapter I. Introduction 
 
1. General notions on peptide and protein structure and function 
 
Peptides and proteins are fundamental molecules characterizing living organisms. Their structure 
and function are both very essential in every process within living cells. Conventionally, proteins 
are polypeptide chains comprising more than 50 amino acids. Their size is extremely variable 
and goes from several hundred to several thousand kilo Daltons depending on the protein. They 
possess a wide range of functions, for example they function as catalysts, transport and store 
other molecules such as oxygen, provide mechanical support and immune protection, generate 
movement, transmit nerve impulses, and or control growth and differentiation. Peptides have 
also very relevant physiological functions, acting in particular as hormones, neurotransmitters, 
cytokines and growth factors. 
Proteins are the most abundant macromolecules in living cells, representing more than half of 
their dry weight. For that reason, in 1838, the chemist Gerardus Mulder proposed to call them 
proteins from the greek proteios, meaning “of primary importance”. At that time, the 
extraordinary properties of those macromolecules were totally unknown since their structure and 
composition remained a mystery. 
A century later, L. Pauling and R. Corey1 deduced by x-ray crystallography the two main 
structural features of proteins: the α-helix and β-sheet, now known to form the backbones of tens 
of thousands of proteins. 
Proteins and peptides are linear polymers built of monomer units, the amino acids, forming 
covalent bonds called peptide bonds (Figure 1). 
H2N
OH
H
N
N
H
R
O
polar
hydrophobic
charged
O Ri
Ri-1 O
H
OH C-terminal
extremity
N-terminal
extremity
n  
Figure 1. General structure of an L-amino acid (left). General formula of a protein formed by n peptide 
bonds (right). 
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Remarkably, proteins and long peptides spontaneously fold up into three-dimensional structures 
that are determined by the sequence of amino acids in the polymer.  
Proteins and peptides are built from a repertoire of 20 amino acids. Each amino acid is an α-
amino acid, containing both amine and carboxyl functional groups, where the amine function is 
in α position of the acid function. 
Each amino acid varies from one another by its side chain (R), which gives to amino acids 
distinctive chemical specificities that can be classified in three different groups owing to their 
chemical reactivity:  
(a) polar 
Uncharged polar amino acids are: Serine, Threonine, Cysteine, Tyrosine, Asparagine and 
Glutamine residues. 
(b) charged 
Charged amino acids are: Aspartic acid, Glutamic Acid, Lysine, Arginine, and Histidine. 
(c) hydrophobic 
Hydrophobic uncharged and non-polar amino acids are: Glycine, Alanine, Valine, Leucine, 
Isoleucine, Proline, Phenylalanine, Tryptophane and Methionine.  
Among those amino acids, proline is a particular residue because its ring structure makes it more 
conformationally restricted than the other amino acids. 
In naturally occurring amino acids, the stereochemical configuration of the chiral center is 
exclusively L. The D forms of amino acids are extremely rare.  
 
1.1. The peptide bond 
A peptide bond (or amide bond) is formed when two amino acids react together via a 
condensation reaction with the loss of a water molecule. In this bond, the non-linking electron 
pair of nitrogen is conjugated with the double bond of the carbonyl oxygen group to give rise to 
two mesomeric forms (Figure 2). The planarity of the peptide bond reduces the geometry around 
the bond to only two conformers: trans and cis. In the trans configuration, the two α-carbon 
atoms are on the opposite sides of the peptide bond. In the cis configuration, these groups are on 
the same side of the peptide bond. Almost all peptide bonds in proteins are trans because the 
steric hindrance of amino acid side chains clearly penalizes the cis conformation in comparison 
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to the trans conformation. Only amide bonds followed by a proline residue present 10% of cis 
conformation. 
C!i N
H
C!i+1
O
R1
R2
C!i N
C!i+1
O
R1
R2
N
R2
HO
R1
C!i C!i+1
Conformation trans Conformation cis
 
Figure 2. Cis-trans isomerization of the peptide bond. 
 
1.2. Torsion angles and Ramachandran plot 
Contrary to amide bonds, which can only adopt cis or trans conformations, the phi (φ) (between 
N-Cα) and psi (Ψ) (between C-Cα) torsion angles are relatively flexible (Figure 3). 
Nevertheless, because of steric interferences between atoms only some of the possible 
combinations of φ and Ψ angles are allowed.  
 
Figure 3. Spatial representation of a polypeptide chain to demonstrate the torsion freedom of a peptide 
unit. Only the N-Cα and Cα-C bonds can rotate, with bond angles designated φ and Ψ. 
 
This was analyzed by Ramachandran and Sasisekharan2, who used solid sphere models of amino 
acids to determine the range of allowed values for φ and Ψ and reported the results in the so-
called Ramachandran plot as depicted in the figure below. 
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Figure 4. Ramachandran plot. The gray and green regions indicate the allowed combinations of φ and Ψ 
angles for all residues except Gly and Pro. β-sheet conformation is found for 90< Ψ< +180 and -
180<φ< -60, right handed helix is found for -60<Ψ< +30 and -120<φ< -30, left handed helix is found 
for 0<Ψ< +60 and -45<φ< +90. 
1.3. Peptide and protein structures 
 The primary structure of a peptide or a protein corresponds to the linear arrangement of 
the amino acid residues in the polypeptide chain. The position of each amino acid in the 
sequence will determine how the chain will fold and adopt its secondary structure. 
 The secondary structure is the local conformation of a polypeptide chain and corresponds 
to the first level of organization of the polypeptide chain in the space. It results from the 
tendency of each amino acid residue to adopt defined combinations of dihedral angles φ and 
Ψ and also from  the establishment of hydrogen-bonding patterns between the carbonyls and 
amide protons along the chain. The two most frequent secondary structures are the α-helices and 
the β-sheets.  
 The tertiary structure refers to the spatial arrangement of the secondary structure units; it 
is the complete three-dimensional structure of a polypeptide chain. 
Proteins, which are built of several polypeptide chains, exhibit a fourth structural level, called 
the quaternary structure.  
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Figure 5. The four levels of protein structure. 
1.4. The random coil 
Proteins fold into a well-defined structure after their synthesis on a ribosome. However, small 
peptides and some polypeptide segments of proteins do not adopt a specific conformation due to 
a lack of amino acid side-chain interactions and because free rotation can take place around 
every bond of the backbone. This absence of specific interactions and the rotation freedom 
generates randomly oriented subunits, resulting in an unfolded state, called random coil. 
1.5. The β-sheet 
One of the major components found in proteins is the β-sheet. The basic unit is the β-strand, 
with the polypeptide almost fully extended. The dihedral angles’ region corresponding to β-
strands in the Ramachandran plot is between φ,Ψ = -120°, +130°. This extended conformation is 
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stable only when incorporated into a β-sheet, where hydrogen bonds with close to optimal 
geometry are formed between the peptide groups on adjacent β-strands. Adjacent strands can be 
either parallel or antiparallel, and the stereochemistry of the strands in the two cases are slightly 
different, such as the hydrogen bonding pattern between the two strands (Figure 6). 
 
Figure 6. Antiparallel and parallel β-sheet bonding patterns. 
 
1.6. The α-helix 
The α-helix is the major element of secondary structure in proteins. It was first described by 
Linus Pauling in 19511. α-helices are formed when a stretch of consecutive residues have a φ, Ψ 
angle pair approximately -60° and -50° (Ramachandran plot). The α-helix is right-handed in 
Nature because of the natural occurrence of L-amino acids. It has 3.6 residues per turn with 
hydrogen bonds between C=O of residue n and NH of residue n+4; the vertical distance between 
each turn is 5.4 Å. Each peptide unit in an α-helix has a dipole moment arising from the different 
polarity of NH and CO groups, these dipole moments are also aligned along the helical axis, 
which results in a partial positive charge at the amino end and a partial negative charge at the 
carboxy end of the α-helix3 (Figure 7). 
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Figure 7. Secondary structure of an α-helix (left) and its dipole moment. 
 
It is worth mentioning that α-helical motifs play a key role in many biological processes; for 
example, the key receptor-binding component in peptide hormones, such as neuropeptide Y4 or 
calcitonin5, have a bioactive helical conformation; furthermore, sequence specific DNA-binding 
proteins often employ α-helical motifs as the DNA recognition element6; eventually, the 
hemolytic activity of melittin and alamethicin peptides are believed to be linked to their helical 
structure7. 
1.7. Initiating α-helices using Ncap templates 
As we have previously seen, the two most common arrangements in proteins are helices and 
sheets. However, the α-helix is not a stable conformation in short polypeptides of fewer than 20 
residues because it lacks specific stabilizing interactions8. In 1959, Zimm and Bragg9 (and 
Lifson and Roig shortly afterwards) defined two parameters, the helix initiation constant (σ) and 
the propagation constant (s), to assess α-helix stability in peptides. The Zimm-Bragg equation 
gives K = [helix]/[random coil] = σsn-1, where n corresponds to the number of residues in the 
sequence. The initiation constant reflects the probability of aligning the first three residues in an 
α-helical conformation. Without stabilizing hydrogen bonds, this is a highly disfavored process, 
due to the repulsive interactions between the aligned dipoles and the loss of entropy. The 
propagation constant s reflects the likelihood of an amino acid residue adopting α-helical torsion 
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angles, when added to the end of a pre-existing helix. And while initiating the helix is paid only 
once for each helix, propagating it multiplies the statistical weight by one additional s-value for 
each hydrogen bond. 
To overcome the problem of initiating helices, Baldwin and coworkers10-12 added conformational 
constraints like salt bridges or charged groups at both termini of the sequence to force the 
peptide into α-helical conformation. Shortly after Kemp13 (and several other groups afterwards) 
developed rigid synthetic templates known as N-caps providing hydrogen bonding acceptors for 
the first four amide protons in the sequence that normally lack them (Figure 8). One difficulty in 
the design and synthesis of such N-Caps lies in the requirement to align H-bond acceptors in the 
correct geometry for helix initiation.  
 
Figure 8. A short peptide has a random coil conformation in aqueous solution and once an N-cap 
nucleating template is added to the sequence, the peptide adopts an α-helical structure. 
Peptide 
Random Coil  
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2. Protein folding and misfolding 
The complex machinery of protein folding is an amazing and fascinating process. How a protein, 
after its synthesis on ribosome, will fold and adopt its well-defined three-dimensional structure, 
essential for its precise function in the cell, is still today not completely understood. Many 
parameters have to be taken into account in protein folding, most notably, its amino acid 
sequence and the cellular environment surrounding the polypeptide chain. The amazing 
recognition and catalytic characteristics of proteins are deeply rooted in their three-dimensional 
structure. Whether they are involved in enzymatic catalysis, immune response, reception and 
emission of stimuli or in the expression and organization of genetic information, their particular 
shape is the key of their success. The stability of the defined structure of a protein is the result of 
the sum of covalent bonds, like disulphur bridges, and a full set of non-bonding interactions like 
Van der Waals interactions, hydrogen bonds, dipolar interactions and hydrophobic packing. The 
latter results from the tendency of hydrophobic residues to form a compact core in the middle of 
the entity while hydrophilic ones tend, in contact with water, to face outwards, creating a dense 
complex surface. 
If most proteins spontaneously fold into their native state, some require the help of enzymes 
called chaperones to assist them to achieve their proper folding. However, if the folding is 
unsuccessful, the polypeptide is directed to the proteasome – a large multisubunit protease - for 
degradation.  
Ensuring accuracy in protein folding is crucial for maintaining proper cellular function. Protein 
misfolding can have dramatic effects on health. 
Several diseases are caused by a loss of protein function because the misfolded proteins have 
been degraded by the proteasome. Other misfolding diseases are caused by conformational 
changes coupled to the aggregation of misfolded proteins outside the cell, beyond the influence 
of intracellular quality control systems. The major representatives of these disorders are the 
amyloidoses, characterized by insoluble extracellular deposits of protein aggregates occurring in 
the post-mitotic environment of the neuron and they include Alzheimer’s and Parkinson’s 
disease. 
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Figure 9. Regulation of protein folding in the Endoplasmic Reticulum (ER). 
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3. Alzheimer’s disease 
Dementia is among the most feared consequences of growing old, and with the aging of the 
populations, its prevalence is expected to increase in most industrialized countries in the coming 
decades. Indeed, Alzheimer’s disease (AD), which is a devastating neurodegenerative disorder 
affecting millions of individuals and for which, 100 years after its discovery, there is still no 
cure, accounts for more than 60% of cases of dementia14, 15. 
 
Figure 10. Brain cross-section as seen from the front. The cross-section on the left represents a brain 
from a normal individual and the one on the right represents a brain with Alzheimer's disease. 
 
The disease is named after a Bavarian neuropsychiatrist, the Dr. Alois Alzheimer, who first 
encountered in 1901 Auguste D., a 51 years old woman, who was suffering from progressive 
changes in her personality. She suffered notably from reduced comprehension and memory, 
aphasia, disorientation, unpredictable behaviour, and paranoia. Dr. Alzheimer, who had never 
encountered a patient with such symptoms before, was fascinated by Auguste D.’s case and 
decided to examine her more closely16. Over time, her state generally worsened, and in her final 
year, she became completely apathetic and spent most of her time hunched up in bed. After her 
death in 1906, Alzheimer autopsied her brain and discovered dense deposits outside and around 
the nerve cells called senile plaques, composed of deposits of Amyloid-β peptide and found to 
be common in the brains of people with senile dementia. But he also observed the presence of 
twisted bands of fibers, inside the nerve cells, known as the neurofibrillary tangles. These tangles 
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are composed of hyperphosphorylated Tau protein. Those findings were first presented and 
published 1906 and in 1911 and still remain today the key diagnostic features of AD17-19. 
 
Figure 11. Hippocampus from a neurologically normal individual and an individual with confirmed 
Alzheimer’s disease.  
 
3.1. Neurofibrillary tangles in AD 
Neurofibrillary tangles (NFT) are one of the pathologic hallmarks of Alzheimer’s disease20, 21 
and many other neurological diseases, such as, amongst others, amyotrophic lateral sclerosis, 
corticobasal degeneration and supranuclear progressive paralysis. 
Neurofibrillary tangles are intracellular fibrillar aggregates of the microtubule-associated protein 
tau that exhibit hyperphosphorylation and oxidative modifications. Microtubules are strongly 
involved in intracellular transport processes and are essential in the development of cell 
processes and establishment of cell polarity22, 23. 
Under physiological conditions, tau is a microtubule-associated protein (MAP) regulating the 
formation of axonal microtubules23, signal transduction24 and neurite outgrowth25. The state of 
phosphorylation of MAPs, balanced by protein kinases and phosphatase, plays a pivotal role in 
modulating microtubule networks26. However, abnormally hyperphosphorylated Tau protein 
accumulates and aggregates to paired helical filaments (PHFs) finally leading to 
neurodegeneration27 (see Figure 12). Interestingly, hyperphosphorylation of tau also blocks APP 
trafficking, suggesting that this tau and elevated levels of Aβ might be linked28. However, a 
recent study carried out by Goldsbury et al. demonstrated that inhibition of APP trafficking by 
tau protein did not increase the generation of Amyloid-β peptides28. 
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Figure 12. Comparison between a healthy neuron and a dead neuron comprising amyloid plaques and 
neurofibrillary tangles. 
 
3.2. From Amyloid Precursor Protein to Amyloid β   
The Amyloid Precursor Protein (APP) is localized to chromosome 21 and is expressed in many 
cell and tissue types including endothelia, glia and neurons of the brain. Within its polypeptide 
chain it bears the sequence of amyloid β (Aβ) 40 and 42, thought to play a key role in the 
pathology of AD. Three major isoforms of the protein exists, APP770, APP751 and APP695. The 
brain seems to produce predominantly the 695 amino acid isoform and thus this isoform has 
received the most attention in research on AD29. 
This transmembrane protein with a large extracellular amino-terminal domain and a small 
cytoplasmic domain can be localized to many membranous structures in the cell such as 
endoplasmic reticulum and Golgi compartments, as well as to the cell membrane. Although its 
exact role is not fully understood, it seems to have an important function in cell adhesion, 
intercellular communication and membrane-to-nucleus signaling30. 
Unlike most receptors, APP is sensitive to proteolytic cleavage. Three main proteolytic cleavage 
sites (the β, α and γ sites) have been identified: two close to the membrane and one within the 
transmembrane domain. The full-length Aβ is generated by the β-secretase cleavage at the β-
cleavage site, between residues 596 and 597. It releases a sAPP (the sAPPβ) and a membrane 
bound peptide (C99) containing the Aβ domain. C99 undergoes further cleavage by γ-secretase 
resulting in the two forms of Aβ, Aβ40 and Aβ42 (Figure 13). 
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Figure 13. Diagram of the cleavage of Amyloid Precursor Protein (APP) by the sequential events of 
different secretases, which result in the metabolic products of Aβ peptide. Above: representation of full 
length APP spanning the membrane. Below: enlarged, transmembrane segment of APP showing site 
action of secretases31. 
 
It was formerly thought that Aβ formation was a result of aberrant APP processing, but it is now 
clear that Aβ is a normal product of APP metabolism since it is also found in normal human 
cerebrospinal fluid and is believed to play a role in axonal transport of APP32. 
However, the mechanism by which Aβ accumulates and becomes toxic to neuronal cells leading 
to AD is still the subject of massive international research efforts. Today, there are increasing 
evidences suggesting that there is a link between induced oxidative stress and conformational 
changes occurring in Aβ, leading to neurotoxicity33-35.  
 
3.3. Understanding Amyloid β  misfolding and its toxicity 
Hundred years after the discovery by Dr. Alois Alzheimer of amyloid plaques in the brain of 
Auguste D suffering from dementia, the mechanism of amyloid formation and toxicity still 
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remains elusive. However, the clinical importance of AD has boosted intensive research in the 
mechanisms of Aβ folding and self-assembly. 
Early studies clearly demonstrated that aggregation of Aβ was essential for toxicity, but 
characterization of the assemblies that formed in vitro was limited, and it was assumed that since 
amyloid fibrils were detectable, these assemblies mediated the observed toxicity. Yet, it is 
known that there is a relatively weak correlation between the severity of dementia and the 
density of fibrillar amyloid plaques36-38.  
Moreover, there is growing evidence suggesting that early, diffusible oligomers (for example, 
dimers, trimers, and tetramers) of Aβ could themselves be toxic to synapses39-42, whereas the 
abundant fibrils of mature amyloid plaques represent a relatively inert reservoir of amyloid β 
protein that is in equilibrium with the smaller, biologically active oligomers43-45. Those β-sheet-
rich oligomeric intermediates exist as a heterogeneous mixture of aggregates of various sizes and 
morphologies (globular, chainlike, and annular structures) and are collectively called 
protofibrils46-48. 
 
Figure 14. Schematic diagram showing the different levels of structure, from the continuous, hydrogen-
bonded β-sheet within a protofilament to the organization of the protofilaments in the amyloid fibril49. 
There is also considerable evidence that the effects of an Aβ protein-initiated inflammatory and 
neurotoxic process include excessive generation of free radicals and oxidative injury to proteins 
and other macromolecules in neurons43. 
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Although significant progress has been made in the resolution of structural properties of amyloid 
fibrils, little is known about the events leading to the aggregation process. Several kinetic studies 
have suggested that fibril formation is a two step process, comprising an initial lag-phase, in 
which nuclei are formed, followed by an exponential or polymerization phase, in which early 
protofibrils grow and assemble to render mature amyloid fibrils, which are then in equilibrium 
with Aβ monomers (Figure 15). 
 
Figure 15. Amyloid fibril formation by nucleation-polymerization.  
 
The nucleation step is the rate-limiting step in the process of amyloid formation. The addition of 
pre-formed fibrils to the solution reduces substantially the length of the lag phase in a 
concentration dependent manner. This phenomenon is known as seeding. Addition of small 
amounts of seed can have dramatic effects in speeding up the process of amyloid formation. 
After nucleation occurs, various assemblies exhibiting structural and morphological 
characteristics of an increasingly complex nature (micelle-like aggregates or spheroids, 
protofibrils, protofilaments) populate sequentially to finally render mature amyloid fibrils. 
In 2006, Lansbury and Lashuel50 published a state-of-the-art review on the protein aggregation 
issue. They explain that due to the greater understanding of the protein fibrillization process in 
vitro, researchers are now focusing on which species are neurotoxic and are trying to elucidate 
the pathway by which they cause neuronal dysfunction leading to disease and death. For the last 
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15 years, the “amyloid cascade hypothesis” has driven most of the research done in AD51. It was 
thought that protein aggregation was the trigger of the cascade of events resulting in 
neurodegeneration and disease. However, it is difficult to find a correlation between protein 
deposits, neuronal dysfunction, neuronal loss and severity of symptoms at the time of death. It is 
also difficult to trace in vivo the early stages of the disease during which oligomers and 
protofibrils forms due to a lack of technical methods. Nevertheless, significant progress has been 
made in that field and it will soon be possible to track the natural history of protein aggregation 
and correlate it with disease progression52, 53. At present, it is already possible to detect in vivo 
fibrillar amyloid plaques with a positron emission tomography imaging reagent, but since 
fibrillar amyloid assemblies occur relatively late in the disease, it would be more useful to have 
analogous reagents targeting early amyloid species. 
Furthermore, a large amount of results has emerged from biophysical studies, providing a 
mechanistic rationale to better explain the effects of disease-causing mutations, but the major 
issue here is that the idealized experimental systems have poor resemblance to the complexity of 
the brain. 
In the review, Lansbury and Lashuel discuss also various hypotheses on neurodegeneration that 
have been proposed up-to-now, to find a rational between the results that have emerged from in 
vitro and in vivo studies. They ask what can be done to refine and clarify the current models and 
what needs to be done in order to produce disease-modifying treatments for neurodegenerative 
diseases and to identify presymptomatic individuals who could benefit from such treatments. 
They demonstrate that, although the techniques have significantly evolved, it remains difficult to 
eliminate any hypothesis since important diagnostic tools are still missing. However, they 
provide relevant information to confirm that the route of oligomers and protofibrillar aggregates 
as toxic species, stands heads above the rest. 
Furthermore, Lührs et al.54 published in 2005 a very important finding on the 3D structure of Aβ 
determined by NMR studies. Their findings suggest that Aβ misfolds by arranging itself into two 
β-sheets that run along the fibril axis. Sheet β1 is formed by residues 18-26, and sheet β2 is 
formed by residues 31-42 (Figure 16). They demonstrated that intersheet contacts are formed 
between residues F19/G38 and A21/V36 and a salt bridge between residues D23 and K28.  
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Figure 16. 3D structure of Aβ(1-42) fibril54. 
The structure of Aβ(1-42) protofilament explains the sequence selectivity, the cooperativity and 
the unidirectionality of the fibril growth. It also provides a structural explanation for the working 
mechanism of current Aβ fibrillization inhibitors.  
This study opens new perspectives in the comprehension of amyloidogenesis and may help in 
the development of anti-AD drugs. 
3.4. Therapeutic strategies: state-of-the-art 
Over the past 20 years, enormous progress has been made in both the diagnosis and treatment of 
dementia and in particular AD. However, due to the complexity of the disease, it is still 
nowadays only possible to slow down the symptoms that accompany the early stages of the 
disease onset. There is still no efficient remedy able to completely stop the gradual decline in 
memory, leading to dementia and ultimately to patient’s death. The drugs that are on the market 
aim at improving the patients’ life by decreasing symptoms like anxiety, insomnia or depression, 
they also provide improvement of the patient’s memory and concentration.  These agents act 
specifically in regulating the neurotransmitters acetylcholine and glutamate.  
Acetylcholine (ACh) is a small neurotransmitter allowing nerve cells to communicate with each 
other. It is synthesized in neurons of the CNS and PNS by the enzyme choline acetyltranferase 
Chapter I  Introduction 
 
 19 
from choline and acetyl-CoA. The successful release and uptake of ACh between neurons is 
followed by its clearance by the enzyme acetylcholinesterase (ACh E), it re-establishes the 
sensitivity of neurons and is essential for proper muscle function.  Several observations have 
demonstrated that during the progression of AD, the levels of ACh decline, and thus a 
therapeutic strategy was to develop compounds capable of inhibiting ACh E degradation in order 
to keep an appropriate level of ACh in the brain.  Those ACh E inhibitors (Donepezil, 
Rivastigmin and Galantamin) have shown favourable, albeit mild, effects on cognitive 
impairment55, 56. 
Glutamate is another important neurotransmitter, which plays a crucial role during the 
development of dementia. Glutamate found in hippocampal neurons is involved in learning and 
memory processes. Contrary to acetylcholine, secretion of glutamate is increased during the 
development of AD, causing calcium ions to enter cells via NMDA receptors channels, leading 
to neuronal damage and cell death. Memantine, an NMDA receptor antagonist, is the only drug 
of this type on the market and works by preventing glutamate from binding to the post-synaptic 
NMDA receptors, thereby decreasing post-synaptic calcium influx through NMDA channels. 
This treatment as well improves the symptoms but does unfortunately not cure the disease57-60.  
Several studies also support the fact that statin drugs, widely used cholesterol-lowering drugs, 
have therapeutic benefits for Alzheimer’s disease. It has been demonstrated that taking statin 
drugs has positive effects on cognition in the elderly and can therefore reduce the risk of 
developing AD61. However, little is known about the mechanism through which the drug works 
and more intense research needs to be done to confirm those observations. 
Considerable evidence shows that oxidative stress is a marker of neurodegeneration and has been 
recently shown to be also involved in the early stages of the pathogenesis of various 
neurodegenerative disorders62-64. Several lines of evidence implied that oxidative damage to lipid 
membranes could disrupt normal neuronal and glial cell functioning, leading to the formation of 
amyloid plaques and to neuronal cell death. Hence, many antioxidants, such as for example, 
flavonoids, tannic acid, vitamin E and C are tested as potiental drugs to prevent AD since they 
might inhibit the production of free radicals and reactive oxygen species. Moreover, it is 
recommended for people at risk to have a diet rich in antioxidants. 
More recent therapeutic strategies have attempted to target the Aβ overload in different ways. 
One possibility is to prevent APP proteolytic processing by inhibiting the action of γ-secretase 
and β-secretase, responsible for Aβ biogenesis65, 66.  These compounds have shown a significant 
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lowering of plasma and CSF Aβ levels. The company Myriad genetics is developing such a 
compound (known as Flurizan TM) that has proven to reduce the level of Aβ42 in cell culture and 
in animal model of AD by modulating the activity of γ-secretase. It is currently being evaluated 
in phase III clinical trials in patients with mild AD. 
Another strategy uses immunization and immunomodulation of Aβ to promote clearance and 
inhibit toxicity67. The aborted clinical trial with the Elan vaccine (AN1792) due to inflammation 
of the brain has provided a large amount of information on how antibodies work to clear Aβ 
from the brain68, 69. Novel methods of antigen approaches are now under investigation and are 
designed to avoid the autoimmune adverse events70.  
A third approach targets directly Aβ itself. This should have a lower risk of developing 
unanticipated side effects, as the accumulated Aβ molecule is restricted to Alzheimer’s disease. 
Moreover, inhibiting the formation of Aβ fibrils seems a reasonable therapeutic strategy, 
because familial mutations that lead to an increase in Aβ concentration result in neuropathology. 
β-breaker peptidomimetics based on the sequence of Aβ16-21 have proved to block both Aβ 
seeding and growth in vitro. However, the pharmacological profile of these compounds is not 
ideal and Soto’s peptide showed toxicity in rats in phase I clinical trials71, 72. 
A new and very promising small molecule from the company Neurochem (Tramiprosate, 
Alzhemed TM) has entered advanced clinical trials73. It acts by binding monomeric Aβ and it was 
shown to cross the blood-brain-barrier as well as to significantly reduce Aβ levels in the brain. It 
has been demonstrated that Tramiprosate affects the levels of soluble Aβ40 and Aβ42 and 
influences its efflux from the brain and catabolism. To date, Tramiprosate completed phase III 
clinical trial in the US and Canada and demonstrated safety, efficacy and disease-modifying 
potential in the treatment of mild-to-moderate AD. It is now under phase III clinical trial in 
Europe.  
Finally, although researchers are focusing mainly on Amyloid β, studies on neurofibrillary 
tangles have progressed and, as with Aβ, small compounds capable of inhibiting aggregation and 
fibrillization of tau protein are now under investigation in vitro74, 75.  
 
Average life expectancy of people suffering from AD has increased in the last few decades 
thanks to intensive scientific research. It seems now clear that targeting a single mechanism of 
action or a single class of compound will not be sufficient to treat and cure this complex illness. 
However, given the scientific and clinical progress that has been made recently, physicians and 
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scientists strongly believe that it will take only few years for the “drugs of tomorrow”, capable of 
stabilizing and preventing the disease, to be available on the market.  
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4. The concept of switch-peptides 
As discussed in the previous chapter, the protein misfolding problem is extremely difficult to 
solve, most notably due to the high propensity of the peptide or protein being investigated to 
self-assemble and aggregate76-79. However, it has become very urgent to be able to follow and 
understand the pathway from the native state of a peptide or protein to its misfolded and 
aggregated state since there is increasing evidence suggesting that this is the key event leading to 
neurotoxicity and to a large number of neurodegenerative diseases50, including Alzheimer’s 
disease on which we have focused our work.  
Our group80 developed a few years ago a new concept for in situ induction of conformational 
transitions called the switch-concept. In this concept switch-peptides are folding precursors, 
which allow not only to induce a defined structure in a peptide but also to study conformational 
transitions relevant in debilitating diseases. 
The designed switch-peptides consist of three segments: a peptide fragment P1 (which can also 
be a conformational induction unit σ), a switch element S and another peptide fragment P2, 
which may serve numerous functions such as host sequence, recognition sequence or bioactive 
sequence (Figure 17). The key conceptual feature of this design is that P1 and P2 are separated 
from each other when the peptide is in the Soff state rendering the peptide more flexible and if P1 
is a conformational inducting unit σ , the effect of σ  is decoupled when the switch is off and its 
effect is set off only when the switch is triggered to re-establish the regular backbone of the 
peptide.  
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Figure 17. ISN-induction of conformational transitions. By removal of Y, an O to N acyl migration 
occurs, restoring a regular peptide bond between P1 and P2 and thus leading to a change in the 
conformation of the peptide, typically from a flexible rc (Soff) to a folded state (Son). These conformational 
changes can be used to study the onset of biological function (A), β-sheet formation (B) and disruption of 
β-structures (C)80. 
Y represents the amino-protecting group of the residues Ser or Thr involved in the formation of 
the switch element S; it can be either a H+, an enzymatic cleavable group or a photolytically 
cleavable group. Due to the different nature of the Y groups, it is possible to introduce in a 
peptide sequence multiple switch elements, which can be triggered orthogonally and 
independently. This technique turns out to be very relevant in the investigation and possibly the 
identification of aggregation “hot spots” in a defined sequence81.  
4.1. The switch element S 
The novel class of switch peptides described in the previous paragraph belongs to the family of 
depsipeptides (depsi means ester in greek). They comprise one or several ester bonds localized to 
specific residues having a hydroxy group in their side-chain, i.e. Ser or Thr. The structural 
modification induced by the substitution of the related amide bond by such flexible non-peptidic 
bonds, leads to a considerable improvement of the solubility (presence of an ionisable amine) 
and the conformational flexibility of the peptide.  
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Figure 18. A serine derived switch element S. 
The subsitution of the amide bond with an ester bond is fairly conservative since both types of 
bonds prefer a trans conformation, are planar and have similar bond angles and lengths, 
preferring similar Ψ and φ dihedral angles82-84. However, they differ in their capacity of forming 
hydrogen bonds. The carbonyl group of the ester bond is a weaker hydrogen bond acceptor than 
the amide bond85. Moreover, the nitrogen atom of the amide bond is a hydrogen bond donor 
contrary to the ester bond (Figure 19). 
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Figure 19. Schematic representation of a normal polypeptide backbone hydrogen bonding (A) and the 
deletion of a hydrogen bond by the incorporation of an ester (B). 
The substitution of one or several amide bonds in a peptide or protein results in a decrease of 
thermodynamic stability. The insertion of ester bonds in secondary structures of type β-sheet or 
α-helix gave an estimation of these effects86. The obtained values have a large variation scale 
(0.7 to 24.6 kcal/mol) depending on the number of hydrogen bonds that are suppressed during 
the incorporation of ester functions in the native protein structure. Schultz and coworkers87 have 
examined the contribution of hydrogen bonds in α-helices to the overall stability of a protein by 
replacing several backbone amide linkages in α-helix 39-50 of T4 lysozyme with ester linkages. 
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It was estimated that a substitution at the N- or C-terminal positions, suppressing a hydrogen 
bond, has a destabilizing effect of about 0.7 and 0.9 kcal/mol. In the middle of the helix, the 
removal of two hydrogen bonds destabilizes the helical structure by 1.7 kcal/mol. 
Kelly et al.88 have demonstrated that the introduction of ester bonds in a small β-sheet protein 
has the strongest destabilizing effect when H-bonds that are enveloped by a hydrophobic cluster 
are perturbed. Mutations at the extremities of the strands exposed to solvent where water 
molecules can compete had much weaker effects. 
Furthermore, the introduction of a CH2 group in the switch-peptide backbone introduces an 
additional degree of flexibility to the peptide. Indeed, the rotation around the Cα-Cβ bond89 
increases the number of possible conformations of the switch-peptides. 
Eventually, the charged amino group in the alpha position can also exert a structure destabilizing 
effect through Coulomb interactions with the polypeptide backbone by interfering with the 
hydrogen bond network. According to the Chou-Fasman parameters90, positively or negatively 
charged amino acids have a lower β-sheet propensity (for example Pβ Glu = 0.37; Pβ Ile = 1.60).  
All these modifications introduced by the switch element in a peptide sequence should modify 
dramatically its structure and function and should result in the disconnection of peptide 
segments, which allows us to study the impact of specific peptide regions on its folding and 
aggregation.  
4.2. O, N-acyl migration 
The concept of switch-peptides is based on the well-known O to N intramolecular migration 
reaction. The reversible O,N-acyl migration reaction was first investigated by Bergmann91 in 
1923. They demonstrated that the migration is pH-dependent and results in the interconversion 
between an O-acyl and an N-acyl analogue. Under acidic conditions, the equilibrium is shifted in 
favor of the O-acyl analogue and, under basic conditions, in favor of the N-acyl analogue. In 
peptides, the reaction is possible at positions of the sequence containing Ser or Thr residues 
(Figure 20). 
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Figure 20. Reversible O to N acyl migration in serine and threonine containing peptides. 
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Today, intramolecular migration reactions find wide applications not only in peptide and protein 
chemistry but also in the area of protecting groups and prodrugs. 
 
Mechanism 
Acyl transfer reactions have been the subject of extensive mechanistic studies and two distinct 
mechanisms have been proposed for this rearrangement92, 93. The key difference between these 
mechanisms is the resulting stereochemistry of the carbon atom connected with the hydroxyl 
group. 
The first mechanism involves the formation of a hydroxyoxazolidine intermediate and leads to a 
retention of configuration as no bond with the asymmetric carbon atom is involved. This 
rearrangement is initiated by the nucleophilic attack of the hydroxyl functionality on the 
electrophilic amide carbonyl to form the hydroxyoxazolidine intermediate. Subsequent ring 
opening of this cyclic intermediate gives the O-acyl analogue. 
The second mechanism involves the formation of an oxazoline intermediate via nucleophilic 
attack of the carbonyl oxygen on the hydroxyl group containing carbon atom. Subsequent ring 
opening results in the O-peptide with a complete inversion of configuration at the chiral carbon.  
Depending on the experimental conditions, either mechanism is possible. When a serine is 
involved, both mechanisms yield the same product, as there are no chiral carbon atoms in the 
side chain. Experimental evidence suggests that steric factors and the choice of solvent used play 
a role in controlling the mechanism by which the rearrangement occurs. Moreover, in addition to 
esters, acyloxy94 and carbamate95 groups, and even amides (upon heating)96 can also undergo 
intramolecular acyl migration via the same mechanisms. 
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Figure 21. Two possible mechanisms of O to N acyl migration. 
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5. Aim of this work  
The work presented in this thesis is within the framework of the switch concept, which has been 
established as a novel tool for the in situ induction of structural and functional properties of 
bioactive peptides (Figure 17). Basically, switch-peptides are used to enable the control and 
onset of secondary structures in peptides having a high propensity to aggregate spontaneously, 
making their investigation difficult to achieve.  
 
In a first study, switch-peptides’ stability in their Soff state was explored and gave us important 
information on the conditions applied in subsequent studies. 
This thesis focuses particularly on switch-peptides derived from amyloid β, known to play a key 
role in the pathology of Alzheimer’s disease. The first objective was to synthesize Aβ(1−42) 
switch-peptides containing multiple orthogonal switch elements to allow for the observation of 
folding events in separate and specific regions of the peptide. It was made possible through the 
sequential activation of orthogonal switch-elements (pathway B, Figure 17). This represents an 
attractive tool for the identification of sequence “hot-spots” crucial for misfolding and 
aggregation.  
 
In a next step, the Aβ(14-24) segment, which has demonstrated to play a key role in Aβ 
misfolding process was excised from the whole sequence and was used in the host-guest 
technique combined with the switch concept in order to study its conformational transition from 
an unfolded flexible precursor (Soff) to its native folded state (Son). Since the handling of 
aggregation-prone peptides is troublesome, making the investigation for potential aggregation 
inhibitors difficult, it was thus of particular interest to examine the potential of host-guest 
switch-peptides for the screening and evaluation of specific Aβ inhibitors. 
 
This has been demonstrated in applying the elaborated host-guest peptides to evaluate switch-
peptides derived from Aβ capable of preventing or even reversing Aβ misfolding and 
aggregation. These peptides are composed of an Aβ recognition sequence and a structure-
disrupting unit containing a pseudoproline, which are linked together via a switch element S, 
rendering the molecule more flexible. This dynamic and flexible system, which separates the 
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recognition and disruption unit should facilitate the insertion of the molecules within Aβ 
aggregates and thus enhance their therapeutic potential in the treatment of Alzheimer’s disease.  
 
Finally, to explore pathway A of the concept (Figure 17), the same sequence of Aβ(14-24) was 
coupled via a switch element S to an α-helix inducing template σ  (Ncap). Using several 
complementary techniques, like CD, EM, ThT or Congo Red, we examined the impact of the 
Ncap unit on helix nucleation and its potential as β-sheet destabilizing agent. 
 
 
 
 
 
 
Chapter I  Introduction 
 
 30 
Chapter II  Results & Discussion 
 
 31 
Chapter II. Results and discussion 
1. overview 
As we have already seen in chapter I, switch-peptides are composed of three different fragments: 
a peptide fragment P1 (which can also be a conformation induction unit σ), a switch element S 
and a second peptide fragment P2 (Figure 17). 
Section 2 of this chapter deals with the stability of the switch element (S) over time when the 
peptide is in the Soff state and exposed to different conditions. 
In section 3, the incorporation of multiple switch elements into the full length Aβ(1−42) to 
disrupt its native structure in order to understand its folding mechanism and to examine the 
folding of specific segments of the peptide is discussed. 
Section 4 concentrates on the host-guest switch-peptide technique, where the segment of Aβ(14-
24), which has proven to be important for Aβ misfolding, has been excised from the amyloid 
sequence and is used with the host-guest technique as a model for studying fibrillogenesis and 
for screening amyloid β inhibitors in vitro. 
The elaboration of switch-peptides as potential Aβ aggregation inhibitors and their inhibitory 
effects on the host-guest switch-peptides studied in the previous section are presented in section 
5. 
Finally, in section 6, the same Aβ(14−25) sequence was coupled via a switch element to an Ncap 
unit to study conformational transitions of type β to α.  it resulted in a drastic increase in 
solubility and a complete disappearance of fibrils. 
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2. Study of the stability of the switch element S in the Soff state 
Under physiological conditions, the O to N acyl migration is a rather fast process, which can 
vary depending on the nature of the protecting group Y (Figure 17), on the nature of the residues 
involved in the switch element and on the conditions that are applied. Here, we discuss the 
stability of the switch element over time to be certain that the O to N acyl migration occurs 
before the ester bond undergoes hydrolysis. Indeed, one critical aspect of switch-peptides is that 
the ester bond constituting the switch element may undergo time dependent hydrolysis. The 
mechanisms for acid and base hydrolysis are described in the following schemes: 
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Scheme 1. Mechanism of the base ester hydrolysis. 
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Scheme 2. Mechanism of the acid catalyzed hydrolysis.   
     
We investigate the stability of switch-peptides towards hydrolysis in the Soff state under different 
conditions, varying the pH of the medium from 4.6 to 8 and the temperature from 25°C to 37°C. 
Switch-peptides, with a H+ as protecting group, have to be dissolved in an acidic medium in 
order to avoid spontaneous O to N acyl migration and hence to retain the Soff state of the peptide.  
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Switch-peptides having a proctecting group removable by the enzyme DPPIV are exposed to pH 
up to 8 as the enzyme’s activity is maximal at pH 8.  
Furthermore, the side chain of the amino acids involved in the switch as well as the size of the 
peptide chain can have an effect on its stability. To study all the parameters, investigations are 
carried out on three different peptides:  
- Fmoc-Leu-(Boc)Ser-OH1 depsidipeptide (peptide 2) 
- Fmoc-Gly-(NVoc)Ser-OH depsidipeptide (peptide 6) 
- Ac-Leu-Cys(ψMe, Mepro)-Ala-(Arg-Pro)Ser –(NMe)Phe-Phe-Asp-NH2 (peptide 19) 
 
The kinetics of the stability were monitored by RP-HPLC assays at pH 4.6, 7.4 and 8 over a 
period of one month at two different temperatures (25°C and 37°C). 
2.1. Stability towards hydrolysis at pH 4.6  
When the protecting group of a switch-peptide is a proton (H+), the peptide has to be first 
dissolved in an acidic medium to keep it in its Soff state and to avoid a spontaneous O to N acyl 
migration. For this reason, the ester hydrolysis rate of peptides 2 and 6 were monitored under 
acidic conditions. The peptides were dissolved in 10 mM acetate and 150 mM NaCl buffer, pH 
4.6, at a concentration of 0.5 mM and were incubated at 25 °C and 37°C. 50 µL aliquots of 
incubated samples were withdrawn at the indicated time points and analyzed by analytical RP-
HPLC.  
Figure 22 represents the time dependent hydrolysis of switch-peptides 2 and 6 in the Soff state at 
25°C and 37°C, respectively. 
 
                                                
1 We follow the proposed nomenclature for depsipeptides. See: S. V. Filip, F. Cavelier, J. Pept. 
Sci. 2004, 10, 115-118. 
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Figure 22. Hydrolysis of peptides 2 and 6 over 25 days, at pH 4.6, 25°C and 37°C. 
 
Figure 23. pseudo-first order kinetic plot of peptide 2 and 6 at 37°C, pH 4.6. 
 
For peptides 2 and 6 we observe that the degradation of the ester bond follows a pseudo-first-
order kinetic (Figure 22 & Figure 23). In all cases, the hydrolysis reaction was found to be very 
slow under acid conditions at pH 4.6, showing substantial stability over a 48h incubation at 37°C 
(less than 2% degradation). 
2.2. Stability towards hydrolysis at pH 7.4  
In order to test the stability of peptides 2, 6 and 19 at physiological conditions, samples were 
dissolved in 10 mM PBS and 150 mM NaCl buffer, pH 7.4, at a concentration of 0.5 mM and 
incubated at 25 °C and 37°C. At various intervals, 50 µL aliquots were withdrawn and injected 
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in analytical RP-HPLC. Figure 24 shows the HPLC chromatograms of peptide 6 at time 0 and 
after 24h at pH 7.4 and 37°C. After 24h the HPLC shows three distinct peaks at Rt = 16.3 min, 
22 min, and 24.4 min respectively, two of them corresponding to the degradation products. The 
peak at Rt = 16.3 min corresponds to the fragment NVoc-Ser-OH and the peak at Rt = 22 min to 
the fragment Fmoc-Gly-OH of the depsipeptide after hydrolysis. The area of the Soff peak after 
24h at 37°C corresponds to about 87% of the Soff peak at time 0, which means that the peptide 
underwent 13% hydrolysis after that incubation period (see also Figure 25).  
 
  
Figure 24. HPLC chromatogram of peptide 6 at t = 0 and after 24h at physiological conditions. 
 
For the six different assays, the percentage of hydrolysis of the Soff state was plotted against time 
to compare the influence of the temperature on the different switch-peptides (Figure 25).  
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Figure 25. Hydrolysis of peptides 2, 6 and 19 over 48h, at pH 7.4, 25°C and 37°C. 
 
The above kinetics reveal that the fragility of the ester bond clearly depends on the bulkiness of 
the side chain of the amino acid composing the ester, but does not seem to depend on the chain 
length of the peptide. Indeed, we observe that peptide 6, containing a glycine residue, shows 
increased susceptibility towards hydrolysis compared to peptide 2 containing a leucine (23% for 
peptide 6 after 48h compared to 5% for peptide 2). Peptide 19, the longest peptide chain among 
the three peptides, having a switch element composed of an alanine residue is more stable than 
peptide 6 but less than peptide 2 containing the bulky side chain of leucine to protect against 
degradation.  
Increased peptide stability was observed at lower temperature (25°C), showing less than 5% 
hydrolysis under otherwise identical conditions.      
 
2.3. Stability towards hydrolysis at pH 8 
0.5 mM of Peptides 2, 6 and 19 were dissolved in 10 mM Tris and 150 mM NaCl buffer, pH 8 
and were incubated at 25 °C and 37°C. Following incubation, the percentage of hydrolysis was 
determined as outlined above.  
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Figure 26. Hydrolysis of peptide 2, 6 and 19 over time, at pH 8, 25°C and 37°C. 
 
The results depicted in Figure 26 show that under alkaline conditions all three peptides were less 
stable relative to milder or more acidic conditions. Moreover, as previously observed at acidic 
and neutral pH, peptide 2 having the bulky and hydrophobic side chain of a leucine residue is 
more stable than peptide 6 containing a glycine and peptide 19 containing an alanine. However, 
for all three peptides less than 10% hydrolysis was recorded after 5h, and the O to N acyl 
migration is a fast reaction, which is complete within hours if not minutes. Thus the depsi-
peptides are stable long enough to allow for the migration to occur.  
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2.4. Conclusion 
The findings on the ester bond stability show that switch-peptides in the Soff state have a 
substantial degree of stability in acidic, neutral or basic environments. The obtained data indicate 
that the optimum pH for maximum stability is in the region of pH 4-5 for the three peptides. 
With increasing pH, the rate of hydrolysis increases and, depending on the nature of the switch 
element, relatively significant degradation can be observed at alkaline pH and 37°C.  
Moreover, these results indicate that steric hindrance, caused by branched alkyl groups97-99 in the 
side chain of the amino acid composing the switch element, significantly decreases the 
hydrolysis rate of the ester bond at 37°C and to a lesser extent at 25°C.  
These results provide significant information on the handling of switch-peptides, information 
that is of particular importance for the work done in the context of this thesis. Notably, it proves 
that significant hydrolysis does not occur before O to N acyl migration is complete. It also 
provides us with valuable information on the time frame in which switch elements in the Soff 
state remain stable in solution at various pH and temperature. It is particularly important to know 
the ability of switch-peptides for remaining in an unfolded conformation in the Soff state. Finally, 
these results validate the foundations of the switch concept.  
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3. Studying the folding mechanism of the full length amyloid β  peptide using 
switch-peptides 
 
3.1. Background and design 
 
As well known from systematic research on β-sheet forming oligopeptides, a detailed 
investigation of these processes is strongly hampered by the strong tendency of the involved 
peptides for spontaneous self-assembly and aggregation, limiting their experimental 
accessibility100. Moreover, Protein folding is a difficult process to simulate with classical 
dynamics as secondary structures can form in microseconds and because this process involves an 
ensemble of transition states difficult to monitor with the existing techniques101-103. To overcome 
this intrinsic problems in the preparation and investigation of β-sheet forming peptides, we have 
seen in the introduction chapter that our laboratory has recently developed a new concept80, 100, 
104, called the switch concept. Here, we apply this concept to amyloid β 1-42 peptide. This new 
generation of amyloid β switch-peptides enables us to start from a flexible, unfolded precursor 
(switch-peptide in the Soff state) in situ. Triggering of the switch elements by removal of the 
protecting group Y allows a spontaneous O to N acyl migration, re-establishing the native 
polyamide backbone and setting off peptide folding (Son) (Figure 27). This versatile method 
allows to follow via different techniques the early folding events and the structure onset as well 
as evolution of the molecule “in statu nascendi” (ISN). 
 
Figure 27. Amyloid β switch-peptide as folding precursors: consecutive trigerring of O, N acyl 
migrations in switch-peptides (Soff) for the onset (Son) of peptide folding and self-assembly in statu 
nascendi (ISN) of the folding molecule104. 
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Simultaneously, the use of pH-induced O,N-acyl migrations for accessing “difficult sequences” 
has been independently described by the groups of Kiso105 and Bienert106.  
Our main goal resides in the identification of nucleation sites (“hot spots”) for fibril formation in 
Aβ sequences as well as to be able to follow its early aggregation steps. To this end, we explore 
in this chapter four different Aβ switch-peptides containing different orthogonal switch elements 
for potential applications in vitro and in vivo. 
 
As Aβ possesses two Serine residues at positions 8 and 26 of its sequence and we know that the 
Serine at position 8 is far away from the critical part of the sequence, in a first generation, a 
switch-peptide was designed with one switch at position 26 (peptide 20). The rational for 
choosing this position for the switch element lies in the findings by Telpow et al.107 and Lührs et 
al.54 that residues Val24-Lys28 form a turn nucleating the intramolecular folding of Aβ 
monomer and from this step, subsequently assemble into Aβ oligomers.  
In a second generation of Aβ switch-peptides, an additional switch element was added at the C-
terminus of the Aβ sequence by replacing Gly37 with a Ser. It seems very appropriate to place a 
switch element S at this position since it has been demonstrated recently by the NMR-based 3D 
structure54 that the C-terminal segment constitutes the core structure of Aβ(1-42) fibrils (peptide 
21 & 22). This modification should not modify the folding behavior of Aβ, the side chain of 
residue 37 being oriented outside of the β-strands (Figure 16).  
In a third generation, the switch-element at position 26 was replaced by a ΨPro as solubilizing 
agent during the synthesis and only one switch element was kept at the C-terminus part  (S37) of 
the sequence (peptide 23). 
We have explored a series of orthogonal triggering systems using chemical and enzymatic 
methodologies81 (Figure 28) for incorporation in Aβ in order to identify nucleation sites for 
fibrillogenesis in the sequence. Due to their proteinogenic cleavage sites, enzymatic triggering is 
particularly useful for modulating the O,N-acyl migration step in vitro. Similarly, photolytically 
cleavable N-protecting groups have been explored and have proved their utility in switch-
peptides. 
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Figure 28. Orthogonal triggering systems. The N(Y)-protected switch-peptide containing an O-acyl 
isoserine (Soff state) as S-element is transformed to native state (Son) by chemical (hν, pH) or enzymatic 
cleavage of Y, triggering spontaneous intramolecular acyl migration at physiologic pH81. 
Using these orthogonal protecting groups, the following four Aβ switch-peptides were 
synthesized and are investigated in this chapter:  
 
 peptide 20:  
1DAEFRHDS8GYEVHHQKLVFFAEDVG (KP)S26  NKGAIIGLMVGGVVIA42 
  enzymatic triggering 
 peptide 21: 
1DAEFRHDS8GYEVHHQKLVFFAEDVG (H+)S26  NKGAIIGLMV (OP)S37 GVVIA42 
     pH triggering  enzymatic triggering 
 
 peptide 22: 
1DAEFRHDS8GYEVHHQKLVFFAEDVG (NVoc)S26  NKGAIIGLMV (OP)S37 GVVIA42 
      hν triggering  enzymatic triggering 
 peptide 23:  
1DAEFRHDS8GYEVHHQKLVFFAEDVG S26(ΨH,Hpro) NKGAIIGLMV (OP)S37 GVVIA42 
     Ser restored after SPPS enzymatic triggering 
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3.2. Synthesis and analytical data 
The Aβ derived switch-peptides were synthesized by solid phase peptide synthesis using the 
Fmoc/tBu strategy on a preloaded NovaSyn TGA resin based on tentagel with a low capacity 
(loading 0.23 mmol/g) (see experimental part). Cleavage of the peptides from the resin was 
achieved by using a mixture of TFA/TIS/EDT/H2O 94:2:2:2 (one hour, twice). Precipitation in 
cold ether gave the crude switch-peptides (Figure 29, insets). The peptides were well soluble in 
water and were purified by semi-preparative HPLC using a C8 column. The obtained peptides 
were analyzed by analytical HPLC (> 95% purity) and mass spectroscopy. The HPLC 
chromatograms and mass spectra of the purified compounds are depicted in Figure 29: 
  
 HPLC of purified peptide (Inset: crude peptide) ESI-MS or MALDI-TOF 
20 
 
 
Mth = 4738 
Mfound = [M+H]+ = 4739 
21 
 
 
Mth = 4752 
Mfound = [M+H]+ = 4753 
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22 
 
 
Mth = 4995 
Mfound = 1250 [M+4H]4+, 1000 [M+5H]5+, 833 
[M+6H]6+, 714 [M+7H]7+ 
23 
 
 
Mth = 4752 
Mfound = [M+H]+ = 4753 
Figure 29. Characterization of Aβ analogs by HPLC (C8 column, gradient 0-100% A in 30 min) and 
Mass Spectroscopy (ESI/MS or MALDI-TOF). 
3.3. Stability studies 
To assess the stability of the different amyloid derived switch-peptides towards aggregation, they 
were incubated at 37°C for two to three days in their Soff states. Electron microscopy, ThT 
fluorescence and CD spectroscopy were used to measure and control the morphology of the 
peptide after each incubation period. 
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Figure 30. CD profile of peptide 23 (Soff state) after 24h and 48h at 37°C in Tris buffer pH 7.4 (upper 
left). ThT fluorescence intensity of peptide 23 in Soff and Son states after 48h incubation at pH 7.4, 37°C 
(upper right). EM images of the peptide in the Soff state after 24h (A) and 48h (B) at pH 7.4, 37°C 
(bottom). 
CD studies of peptide 23 (Soff state) demonstrate that the peptide remains in a flexible random 
coil conformation after 48 hours at 37°C in pH 7.4 Tris buffer. Moreover, ThT fluorescence level 
after 48h was as low as at time zero; EM images revealed the presence of only minor oligomeric 
structures under these conditions, confirming that peptide 23 in its Soff state does not form 
amyloid-like fibrils even after a long incubation period (Figure 30).  
Stability towards aggregation of peptides 20 and 22 was assessed by incubating them at 37°C in 
H20 at 200 µM and in pH 7.4 Tris buffer at 25 µM for two to three days. EM studies revealed 
that peptide 22 comprising 2 switch elements did not form fibrils after 3 days in H20 but showed 
a diminished stability at physiological conditions (oligomeric structures were observed after 24h) 
(Figure 31). 
EM studies of peptide 20 comprising only one switch at position 26 of its sequence showed 
fibril-like structures after two days of incubation in H20; nevertheless, the peptide was stable 
under these conditions for 24h. Moreover, as for peptide 22, the stability towards aggregation of 
peptide 20 was diminished at pH 7.4, EM images revealed a significant amount of oligomers 
after 24h and short fibrils after 48h (Figure 31).  
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 Peptide 22 (Soff state) Peptide 20 (Soff state) 
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Buffer pH 7.4 
 
 
 
 
 
 
Figure 31. Electron Microscopy of peptide 20 and 22 in their Soff state after 24h, 48h or three days 
incubation at 37°C in H20 (peptide concentration = 200µM) and in Tris buffer pH 7.4 (peptide 
concentration = 25 µM). 
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3.4. Folding and aggregation studies 
The folding and aggregation process of the  amyloid β-derived switch-peptides 20-23 were 
investigated by analytical HPLC, CD spectroscopy, EM and ThT fluorescence. The results are 
depicted below. 
 
Peptide 20 
 
Switch-peptide 20 possesses one S element at position 26, which can be triggered by the enzyme 
DPPIV. To study the enzyme-induced acyl transfer, peptide 20 was dissolved in a solution of 
H2O/Tris pH 7.4 (30 mM) (1:3) and 150 mM NaCl at a concentration of 200 µM, 20 µL of 
DPPIV (0.02 unit) were added to the mixture prior to incubation at 37°C. At various intervals, 20 
µL aliquots were taken from the sample and injected to analytical HPLC. Figure 32 shows the 
HPLC chromatograms of the chemical conversion of switch-peptide 20 from its Soff to its Son 
state. However, monitoring of the conversion resulted in broadening and eventual vanishing of 
the Soff peak, which was due to the rapid precipitation of the peptide, accompanied by an 
increase in solution turbidity observed in the vial. As precipitation occurs before the completion 
of O to N acyl migration, monitoring the conversion by HPLC is difficult (see Figure 32).  
 
Figure 32. HPLC chromatograms of peptide 20 obtained for the DPPIV-triggered acyl transfer at S26.   
 
However, we attempted to further investigate conformational transitions and fibril formation of 
peptide 20 by circular dichroism, electron microscopy and ThT fluorescence. To this end, the 
peptide was first dissolved in a solution of H2O/Tris pH 7.4/TFE 35:60:5 (c = 25 µM); TFE was 
added to favor the solubility after the transition from rc to β-sheet. Unexpectedly, we observe at 
time zero a CD spectrum characteristic for a β-sheet with a strong negative cotton effect at λ = 
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218 nm (Figure 33, red curve). Obviously, the content of TFE (5%) promoted β-sheet formation 
in the Soff state. To overcome this problem, a mixture containing 2.5% TFE was prepared and at 
time zero, the spectrum was characteristic of a random coil with a negative cotton effect at λ = 
198 nm (Figure 33, black curve). 
 
Figure 33. CD spectra of peptide 20 in the Soff state at pH 7.4 with 5% or 2.5% TFE. 
Subsequently, acyl migration was triggered in the sample with 2.5% TFE by the addition of 2 µL 
DPPIV enzyme (0.002 unit) and the sample was incubated at 37°C. The conformational 
transition was relatively slow, showing a transformation from rc to β-sheet after 24h. The β-
sheet transition was accompanied by a significant decrease in negative cotton effect at λ = 218 
nm ( Figure 34, green curve), further demonstrating the high propensity of the peptide for 
precipitation. EM images revealed the presence of oligomeric structures after 24 and 48h of 
incubation and, short fibrillar morphology of the peptide was only observed after 4 days of 
incubation. A low remaining concentration of peptide in solution may have accounted for the 
slow onset of fibrillogenesis found with this peptide. It is indeed well-known that fibrillogenesis 
is concentration dependent.  
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 Figure 34. Conformational transition upon O to N acyl migration of peptide 20 monitored by CD in Tris 
buffer pH 7.4/ 2.5% TFE at 37°C (left). Fibril formation followed by EM over a period of 4 days (right). 
Because peptide 20 was difficult to investigate due to its instability towards precipitation (see 
stability studies above) and its rapid precipitation during acyl migration, a new generation of 
amyloid β-derived switch-peptides (peptides 21 and 22) comprising a second switch element at 
the C-terminus of the sequence (position 37) was designed. 
 
Peptide 21 
 
In switch-peptide 21, the central S26 is triggered by adjusting the pH to physiological pH. To 
study the pH-induced acyl transfer, switch-peptide 21 (200 µM) was dissolved in a solution of 
H2O/Tris pH 7.4 (30 mM) (1:3) and 150 mM NaCl. At various intervals, 20 µL aliquots were 
taken, quenched with 10 µL HCl 1M and injected to analytical HPLC. Figure 35 represents the 
acyl migration after triggering S26, restoring native Aβ(1-36). The chromatogram shows a 
gradual decrease in absorbance of the Soff peak and concomitant increase in absorbance of the Son 
peak. This time no precipitation was associated with the activation of S26 suggesting that Aβ(1-
36) has no tendency for spontaneous aggregation. EM imaging confirmed a substantial stability 
found in peptide 21 after 48h, showing that the additional switch at S37 prevents it from 
undergoing fibrillogenesis. 
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Figure 35. Overlay of chromatograms obtained for the pH-induced acyl transfer at switch S26 in peptide 
21. Triggering of S26 restores the regular amide bond Aβ(1-36) (left). EM image of peptide 21 S26on/S37off 
after 24h. 
To trigger switch element S37, enzyme DPPIV (0.002 unit) was added to the solution; O,N-acyl 
migration was again monitored by analytical HPLC by injecting 20 µL aliquots at various time 
points (Figure 36). Here, we observe a gradual decrease in absorbance of peak 2 (S26on, S37off) 
and the increase in absorbance of a new peak (3) corresponding to S26on, S37on. Interestingly, by 
the subsequent enzymatic switching on of the C-terminal segment (37-42), the characteristic 
phenomena observed for native Aβ(1-42), i.e. aggregation and precipitation are initiated as 
monitored by a drastic decrease in absorbance of peak 3 and its complete disappearance after a 
few hours. 
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Figure 36. Overlay of the HPLC chromatograms obtained for the DPPIV-triggered O,N-acyl transfer at 
S37 in switch-peptide 21. At time zero, S26 is on and S37 is off, after 1h15, two peaks are observed 
corresponding to S26on ,S37off  (peak 2) and after restoring the complete Aβ(1-42) sequence, peak 3 (S26on 
,S37on). 
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In parallel, the conformational transition was monitored by CD and EM at 25 µM, 37°C in Tris 
buffer pH 7.4 / 5% TFE. At time zero, the curve corresponding to S26on, S37off was characteristic 
of a random coil, which evolved to a β-sheet conformation after addition of DPPIV enzyme 
(Figure 37).  
 
 
Figure 37. Conformational transition upon pH- and enzyme-triggered acyl migrations from a random 
coil (Soff) to a β-sheet (Son) of switch-peptide 21 monitored by CD in Tris buffer pH 7.4/ 5% TFE at 37°C 
(left). Fibril formation followed by EM over a period of 4 days (right). 
EM studies show that oligomers are formed after 8h and protofibrils start to grow after 24h, 
giving rise to amyloid-like fibrils after 2 days and reaching maturation after 4 days. These 
observations were confirmed by ThT fluorescence (Figure 41), where peptide 21 bound ThT dye 
and reached a plateau after 2 days. 
 
With peptide 21, the sequential triggering of the S elements was restricted to a particular order, 
i.e. S26 had to be switched on first by raising the pH to 7.4; in a second step the enzyme, only 
being active between pH 7 and 8, could be added to trigger S37 at the C-terminus of the peptide. 
Given this order of switching on the S-elements, it was thus not possible to study independently 
the impact of the C-terminal part on the folding of Aβ; therefore, peptide 22, containing two 
orthogonal switches (at position 26 and 37 as well) was designed. Peptide 22 possesses one 
switch protected by NVoc group (photolytic cleavable group) at S26 and one switch at S37 
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cleavable by the enzyme DPPIV. In this particular case, we do not have to follow a specific 
order, i.e. we can trigger either S37 first or vice versa. 
 
Peptide 22 
 
To follow O to N acyl migration, peptide 22 was subjected to HPLC analysis under the same 
conditions as previously for peptide 20 and 21. Here, S37 was triggered first (S26 remained in the 
Soff state). From HPLC monitoring, we can see the disappearance of peak 1 (S26off, S37off) and the 
appearance of the peak 2 (S26off, S37on) over time. Interestingly, by triggering first S37 and letting 
S26 off, i.e. switching on the C-terminal segment (37-42), we already observe a significant 
decrease in absorbance and complete disappearance of the Son peak after a few hours, indicating 
that precipitation and aggregation were already initiated. This gives a first experimental proof of 
the importance of Aβ C-terminal part for folding and aggregation of Aβ(1-42). 
 
 
Figure 38. HPLC chromatograms of acyl migration of S37 in peptide 22. Peak 1 corresponds to switch-
peptide 22 in the Soff state, peak 2 (more hydrophobic) represents the peptide after acyl migration at 
switch S37. 
To further examine the importance of the C-terminus on folding and aggregation, peptide 22 was 
subjected to CD, EM and ThT studies. The peptide was dissolved in H2O/Tris buffer pH 7.4/ 
2.5% TFE to a final concentration of 25 µM. The switch at position S37 was triggered by the 
addition of 2 µL enzyme DPPIV (0.002 unit) at 37°C. At time zero, a strong negative cotton 
effect at λ = 198 nm characteristic of a random coil is observed (Figure 39, black curve). The 
signal evolves over time towards a spectrum corresponding to a β-sheet structure and after 7h30 
the transformation is nearly complete (Figure 40, blue curve). Moreover, EM images revealed 
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that significant amounts of oligomers were formed after 6 hours and amyloid-like fibrils were 
found after two days. This result confirms that the C-terminus part of Aβ(1-42) represents a 
nucleation site for folding and aggregation and that even by letting the position S26 off, 
aggregation  occurred and was as fast as observed for peptide 21. 
 
 
 
Figure 39. Conformational transition upon enzyme-triggered acyl migration from a random coil (Soff) to 
a β-sheet (S37on) of switch-peptide 22 monitored by CD in Tris buffer pH 7.4/ 2.5% TFE at 37°C (left). 
Fibril formation followed by EM over a period of 4 days (right). 
As we have demonstrated that the switch element at position 26 did not seem to have a big 
impact on folding and aggregation of Aβ(1-42) compared to switch element at position 37, the 
design of a peptide containing a single switch element at position 37 (peptide 23) seemed to be 
the most challenging for elucidating folding and aggregation in comparison to previous peptides.   
 
Peptide 23 
 
As before, peptide 23 was subjected to CD, EM and ThT studies to evaluate its folding process at 
physiological conditions and at a concentration of 25 µM. To follow the transition from random 
coil to β-sheet by CD, 5% of TFE was added to the solution. As already seen from the stability 
studies (Figure 30) peptide 23 adopts a random coil conformation for at least two days without 
fibril formation. Here, at time zero, the peptide shows a CD spectrum characteristic of a flexible 
random coil conformation. On triggering O,N-acyl migration by adding 2 µL DPPIV, peptide 23 
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undergoes a conformational transition to a β-sheet structure (negative cotton effect at λ = 220 
nm). EM studies revealed significant amounts of oligomers after 7h30 incubation and mature 
amyloid-like fibrils are formed after two days. These results clearly demonstrate that the C-
terminus of Aβ1-42 plays a key role in the early step of misfolding.  
 
Figure 40. Conformational transition upon O to N acyl migration of peptide 23 (left) followed by CD in 
Tris buffer pH 7.4 at 37°C. Fibril formation followed by EM over a period of 4 days (right). 
 
3.5. ThT kinetic comparison 
In parallel to CD and TEM studies, the detection of fibril formation for the four Aβ-derived 
switch-peptides was followed by ThT fluorescence. It is known that only multimeric fibrillar 
forms, not multiple β-sheet domains in native proteins, are fluorescent with ThT. Therefore, ThT 
is thought to interact specifically with amyloid fibrils; consequently, measuring the level of 
binding of ThT to fibrils is indicative for the kinetics of fibril formation. 
In this experiment, the peptides were incubated under the same conditions as previously for the 
CD and EM studies.  
We observe that peptide 20, shown to have a high propensity for precipitation, does not show a 
strong fluorescent signal compared to peptides 21, 22 & 23 (Figure 41), confirming our earlier 
finding that due to its rapid precipitation, the concentration of peptide 20 remaining in solution is 
too low to enable peptide for aggregation. 
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Figure 41 also shows that after triggering the two switch elements, peptide 21 binds ThT 
fluorescent dye in approximately the same degree as peptide 23 comprising one switch at 
position 37. For peptide 22, in the state S26off, S37on,we observe a lag phase to ThT binding but 
after two days a strong signal comparable to peptide 21. 
 
Figure 41. Kinetics of fibril formation for the four Aβ-derived switch-peptides monitored by ThT 
fluorescence.  
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3.6. Discussion 
 
We have demonstrated that amyloid β-derived switch peptides are powerful tools to identify 
nucleation sites for fibril formation in Aβ sequences and to follow its early aggregation steps. 
The introduction of a single switch element at position 26 of Aβ sequence facilitates the 
synthesis and the solvation of the peptide in aqueous media but is not sufficient to enable the 
investigation of O,N-acyl migration and the subsequent onset of β-structures and fibrillogenesis 
since the peptide precipitates immediately after triggering O,N-acyl migration. However, the 
incorporation of a second switch element at position S37 allowed us to study in more detail the 
processus of misfolding and thus to demonstrate that the C-terminal part of Aβ(1-42), more 
particularly the segment Aβ(37-42) is crucial for fibril formation  and aggregation. 
Moreover, we have demonstrated with peptide 23 that incorporating a single switch element at 
position 37 increases drastically the stability of Aβ towards self -assembly, showing that 
disconnecting the C-terminal segment is sufficient to keep the peptide in an unfolded state.  
These experimental results are in harmony with the 3D-structure of Aβ(1-42) proposed by Lührs 
et al.54 and confirm for the first time the important role of the C-terminus on the rate of fibril 
formation108. 
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4. Host-guest switch-peptides derived from Aβ  as a model for studying 
fibrillogenesis and for screening amyloid β  inhibitors in vitro. 
 
4.1. Background 
Protein misfolding, such as found with Aβ peptide in AD or α-synuclein protein in PD, and its 
accompanying aspect in conformational transitions, has attracted a vast interest in various 
research fields. 
For example, recent research suggests that conformational transitions of amyloid β precursor 
molecules into aggregated, β-sheet-type forms play a key role in the deposition of cerebral 
amyloid plaques characteristic of Alzheimer’s disease. 
It is also important to understand the mechanism of their formation starting from monomers 
because it is becoming increasingly clear that the nonfibrillar intermediates may be the toxic 
species in Alzheimer’s disease40, 109-111. 
It is thus of importance to find a method that could efficiently evaluate the influence of external 
factors such as temperature, pH, inhibitors or β-breakers on the propensity of a peptide to adopt a 
well-defined secondary structure. This method could then be applied to study the conformational 
transition of amyloid proteins from an unordered state into β-sheets. 
This intrinsic problem of protein folding prompted Mutter et al. to apply the host-guest technique 
in combination with the concept of “switch-peptides” studying conformational transitions of 
peptide segments excised from their native sequence80, 112. 
 
The host-guest approach was first introduced in peptide chemistry by Scheraga113 in the early 
seventies. The method consists of incorporating guest residues into a host polypeptide sequence 
having the propensity to fold in an α-helical structure to determine the helix-coil stability 
constants of the 20 naturally occurring amino acids. Few years later, Toniolo and Mutter et al.114-
116 used the host-guest technique to investigate the impact of guest amino acids (in particular Gly 
and Pro) on host peptide sequences having the potential to adopt both helical and β- structures. 
They were able to demonstrate that depending on the conformational preferences of the guest 
residue, the extension of an α-helix forming host peptide could be blocked by a single guest 
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amino acid (natably Pro), or that a single guest amino acid inserted in to a β-sheet forming host 
peptide could destabilize the ordered conformation.  
 
The hydrophobic Aβ(16-20) sequence KLVFF of the Aβ peptide is considered as a key region 
for nucleating self-assembly and oligomerization and therefore the formation of fibrils. However, 
the pentapeptide Aβ(16-20) alone does not form fibrils by itself and thus, residues flanking this 
region are important for Aβ fibril formation. Tjernberg et al.117 identified the shortest fibril-
forming Aβ fragment as being the sequence HQKLVFFAED corresponding to the Aβ(14-23). 
Even though this decapeptide forms fibrils, it does not give CD spectra characteristic for β-sheet 
formation probably due to its low overall propensity for the onset of β-sheets. To elucidate the 
role of this core region in β-sheet and fibril formation, we designed a host-guest system where 
Aβ(14-24) is flanked between two β-sheet promoting (Leu-Ser)n oligomers as host sequences104, 
118. Upon acyl migration i.e. in restoring the regular backbone of the host-guest peptide, it is 
possible to follow the ISN-induction of conformational transitions from random-coil to β-sheet. 
Consequently, host-guest switch-peptides may be used to study the early folding events of Aβ as 
a tool for the screening of Aβ inhibitors and β-breakers, bypassing, the difficulties of handling 
native Aβ(1-42). 
4.2. Design of host-guest switch-peptides 
Two amyloid β-derived host-guest switch-peptides are designed: 
• Peptide 8 (Figure 42), containing a single switch at postion 21 of [Ser21]Aβ(14-24) that 
can be triggered by the enzyme DPPIV. To generate a switch element, Ala 21 has been 
replaced by a Ser residue. 
• Peptide 9 (Figure 52) featuring two switch elements at the N- and the C- terminus of the 
guest sequence Aβ(14-24).  
Peptides 8 and 9 were subsequently used to investigate the spontaneous intramolecular O to N 
acyl migration as monitored by HPLC, the induction of folding events such as self-assembly, β-
sheet (CD) and fibril formation (EM) of the molecule and their use as a screening kit system for 
Aβ fibril inhibitors and β-sheet breakers. 
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4.2.1. Host-guest switch-peptide 8 containing a single switch element S 
 
 
Figure 42. Application of the concept of switch-peptides to host-guest peptide [Ser21]Aβ(14-24) (8) with a 
single switch element at position 21. In the Soff state, the peptide is designed to adopt a random coil 
conformation; after addition of the enzyme DPPIV, the peptide undergoes O,N-acyl migration, inducing 
peptide folding and self-assembly. 
 
Synthesis  
 
The synthesis of peptide 8 was performed in collaboration with S. Dos Santos (PhD thesis 2005, 
EPFL). The peptide was assembled on Rink amide MBHA resin applying the Fmoc/tBu strategy 
as depicted in Scheme 3.  
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Scheme 3. Solid phase synthesis of switch-peptide 8. (i) standard solid phase peptide synthesis according 
to the  Fmoc/ tBu strategy, (ii) Fmoc-Ser(OH)-OH, Boc-Arg(di-Boc)-OH and Fmoc-Pro-OH (30 min); 
(iii) Fmoc-Phe-OH (3eq), DIC (3eq), DMAP (0.5eq), DCM/DMF (4:1), 2h; (iv) TFA/TIS/H2O 95:2.5:2.5, 
2x1h. 
The synthesis was straightforward and the HPLC revealed a major peak identified as the target 
peptide 8 (Figure 43). Some deletion sequences were observed. After purification by preparative 
HPLC, 8 was obtained in a yield of ca 30% (>95% purity). 
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Figure 43. HPLC (C18, 0 to 100% A, 30 min) of crude and purified switch-peptide 8, inset: MALDI-TOF 
of the purified compound (m/z =2300 [M+H]+). 
 
Kinetic studies on folding and fibril formation by HPLC, CD, EM and ThT 
 
To follow the O to N acyl migration, peptide 8 was dissolved in Tris buffer pH 8 at a 
concentration of 400 µM. Subsequently, enzyme DPPIV was added to the mixture. At various 
intervals, 20 µL aliquots were taken and injected to analytical HPLC (Figure 44). 
 
Figure 44. HPLC chromatograms of the enzymatic cleavage of dipeptide H-Arg-Pro-OH from switch-
peptide 8 (Soff) and subsequent acyl migration restoring the regular amide backbone (peptide 8 in the Son 
state). 
While triggering O,N-acyl migration by adding DPPIV enzyme, we observe by HPLC (Figure 
44) the evolution of the cleaved dipeptide Arg-Pro (7.2min), the gradual disappearance of the Soff 
peak (15.2 min) and the onset of a new peak corresponding to the Son state (peak at 15.7 min). 
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We can notice a decrease in absorbance of the Son peak compared to the Soff peak. This 
corresponds to β-sheet formation and precipitation of the peptide. 
In parallel, the conformational transition was monitored by CD and EM at 50 and 20 µM at 37°C 
and pH 8. At a concentration of 50 µM (Figure 45), at time zero, the curve corresponding to the 
Soff state was characteristic of a random coil (rc) structure (blue) but after addition of DPPIV a 
dramatic change from rc to β-sheet conformation is observed. The time course of the process is 
relatively fast, the half-life of β-sheet formation or disappearance of the rc being ca 15 min 
(Figure 45). Similarly, EM studies (Figure 46) show that after restoring the peptide backbone, 
the onset of β-sheet formation results in spontaneous fibril formation. Protofibril formation is 
observed immediately after enzyme addition to the peptide and a large amount of fibrils 
comparable to amyloid β fibrils are observed after 20 minutes. Furthermore, the peptide binds 
ThT dye reaching a plateau at 10 min only. This finding suggests that the lag-time for fibril 
formation of peptide 8 is very fast and that amyloid-aggregates are formed reaching maturation 
after few a minutes. 
 
 
Figure 45. CD monitoring  the conformational transition upon acyl migration from a random coil to a β-
sheet conformation at 37°C in Tris buffer, pH 8 (500 µM) + 10% MeOH and 2.5 mM NaCl (peptide 
concentration = 50 µM). Inset: CD monitoring over time of β-sheet formation at 218 nm (green dots) and 
of random coil disappearence at 195 nm (blue dots). 
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Figure 46. Conformational transition of peptide 8 followed by negatively stained electron micropscopy in 
the absence of DPPIV and after its addition to the solution (see text).  
 
 
Figure 47. Thioflavin T fluorescence kinetics of peptide 8 at 50 µM and 37°C. 
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In contrast, the folding of the peptide at 20 µM (Figure 48 & Figure 49) was significantly slower 
(by factor of 8) compared to 50 µM as shown by the CD spectra. A half-time value for the 
conformational transition from random coil to β-sheet of ca 120 min is observed, confirming that 
the folding and aggregation of peptide 8 strongly depends on the concentration. 
 
 
Figure 48. CD monitoring of the conformational transition upon acyl migration from a random coil to a 
β-sheet conformation at 37°C in Tris buffer pH 8 (500 µM) + 10% MeOH and 2.5 mM NaCl (peptide 
concentration = 20 µM).  
The screening of CD samples by EM revealed the presence of short fibrillar-like structures after 
1 hour (Figure 49). These morphological changes are in agreement with the changes in CD 
minima observed at 195 nm and 218 nm, indicating a slow transition from rc to β-sheet structure. 
β-sheet conversion appeared to be completed after 5 hours, as monitored by the negative cotton 
effect at 218 nm as well as the abundant presence of structurally mature fibrils. The first CD 
spectra (at t = 0, 1h and 1h45) converge in one point at λ = 208 nm, the isosbestic point. This 
observation suggests that at this stage only two states contribute to the CD spectrum, i.e. that rc 
and β-sheet species are in equilibrium. However, after 2h30 the spectra do not converge into this 
point anymore, indicating the presence of multiple species in the solution, i.e. rc, β-sheet and 
soluble oligomeric structures and suggesting that aggregation started. Moreover, Th T 
fluorescence reached a plateau after 7 hours, which confirm our observations (Figure 50, black 
curve). 
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Figure 49. Electron micrographs of peptide 8 incubated at pH 8 and 37°C (c = 20 µM). 
 
Screening of molecules of fibril-destabilizing activity  
 
After the establishment of the methodology, we further probed the potential of host-guest switch-
peptide 8 for the investigation of the effect of molecules known for their Aβ fibril destabilizing 
activity (taken from the literature) upon Aβ fibril formation. For this purpose, we chose 
antioxidants such as tannic acid, wine-related polyphenols (myricetin) and the neurotransmitter 
dopamine119-122 that have been demonstrated to protect the brain from in vitro Aβ toxicity and to 
inhibit formation and extension of amyloid β 1-40 and 1-42 in vitro.  
 
Experiments 
Peptide 8 was incubated for 48 hours under the following conditions: Peptide 8 was first 
dissolved in MeOH/H20 50/50 to a final concentration of 400 µM (stock solution). The solution 
was vortexed for 30 seconds and filtered through a 0.2 µm filter by centrifugation for 5 min at 
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10’000 rpm. 50 µL aliquots of the filtrate were transfered into autoclaved Eppendorf tubes. 750 
µL of Tris buffer pH 8 500 µM + 2.5 mM NaCl and 100 µL of MeOH were added to each tube. 
The inhibitors were dissolved in MeOH at concentrations of 400 to 800 µM and 100 µL of these 
stock solutions were added to the mixture to give the correct final concentration of inhibitor in 
the reaction mixture. 1.5 µL (0.002 unit) of DPPIV enzyme was then added to each vial and 
placed in a water bath at 37°C for 48 hours. Aliquots of 160 µL were removed from the 
incubated samples at different time points and stored at -18°C until further analysis. 
 
Thioflavin T (ThT) and Electron microscopy (EM) analysis 
ThT is a fluorescent dye widely used for the detection of amyloid fibrils due to its relatively 
specific interaction. 
The inhibitory effects on β-sheet formation of peptide 8 of tannic acid, myricetin and dopamine 
were tested using standard analytical techniques of ThT fluorescence and EM as described 
above.  
 
 
Figure 50. Kinetics of fibril formation monitored by Th T fluorescence. Control (black); after addition of 
80 µM dopamine (cyan), 40 µM oxidized dopamine (blue) and 40 µM myricetin (green), 40 µM tannic 
acid (red). 
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Figure 51. TEM images of peptide 8 fibrils A) after 48 h incubation at 37°C, and in presence of 2 eq of 
tannic acid (B), 2 eq of myricetin (C) and 4 eq of dopamine (D). 
 
In the absence of inhibitors, peptide 8 (20 µM) forms fibrils within 5 hours upon enzymatic 
triggering, as can be seen by the fast increase in ThT fluorescence levels (Figure 50). ThT level-
off after ca 6 h indicating saturation in ThT binding and fibril completion. The presence of 
mature fibrils observed by EM after 48 hours incubation time is in agreement with the kinetic of 
ThT binding (Figure 51; A).  
Interestingly, secondary structure formation (rc to β-sheet) of peptide 8 was inhibited in the 
presence of tannic acid (40 µM), myricetin (40 µM) and oxidized dopamine (40 µM). Compared 
to the antioxidants the effect of dopamine (80 µM) is less pronounced within the first 2.5 hours 
of incubation. Nevertheless, significant inhibition was observed after 5 hours incubation 
incubation with dopamine, showing a gradual decline in ThT fluorescence. Most notably, 
fibrillogenesis was completely inhibited in samples co-incubated with the antioxidants tannic 
acid (Figure 51, B) or myricetin (Figure 51,C), as seen by the presence of some oligomeric 
Chapter II  Results & Discussion 
 
 70 
species, whereas residual amounts of short fibrillar structures could be observed in samples 
incubated with dopamine (Figure 51, D). 
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4.2.2. Host-guest switch-peptide 9 disposing two switch elements. 
 
Figure 52. Host-guest switch-peptide 9, containing two switch elements at the N- and C- terminus of the 
guest peptide Aβ(14-24). In the Soff state, the peptide is designed to adopt a random coil conformation, 
after adjusting the pH to physiological conditions, spontaneous acyl migration occurs resulting in peptide 
folding. 
Synthesis 
The Aβ-derived host-guest switch-peptide 9 was assembled on 1 g of Rink amide MBHA resin 
(loading 0.66 mmol/g) according to the Fmoc/tBu strategy (Scheme 4). 
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Scheme 4. Solid phase synthesis (SPPS) of switch-peptide 9. (i) standard solid phase peptide synthesis 
according to the  Fmoc/ tBu strategy, (ii)Fmoc-Val-OH (3 eq), DIC (3 eq), DMAP (0.5 eq), DCM/DMF 
(4:1); (iii) Fmoc-Leu-OH (3eq), DIC (3eq), DMAP (0.5eq), DCM/DMF (4:1), 2h; (iv) TFA/TIS/H2O 
95:2.5:2.5, 2x1h. 
The synthesis was straightforward and the HPLC revealed one major peak identified as the target 
peptide 9 (Figure 53). Only one deletion sequence was observed. After purification by 
preparative HPLC, 9 was obtained in a yield of ca 36% (> 95% purity). 
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Figure 53. Analytical data of switch-peptide 9, left: HPLC (C8, 0 to 100% A, 30 min) of crude 
compound, right: HPLC (0 to 100% A, 30 min) and ESI/MS ((m/z) 1016 [M + 2H]2+, 678 [M + 3H]3+, 
509 [M + 4H]4+; inset) of purified compound. 
Kinetic studies of folding and fibril formation  
 
Conversion of peptide 9 from the Soff to the Son state via O to N acyl migration was followed by 
HPLC. Peptide 9 was dissolved in acetate buffer, pH 4.6 (10 mM) at 400 µM, 37°C. To trigger 
acyl migration, the pH was adjusted to 7.4 by adding 10% PBS buffer pH 7.4 (0.3 M + 150 mM 
NaCl). At various intervals, 20 µL aliquots were taken and injected to analytical HPLC to follow 
the migration (Figure 54). 
 
 
Figure 54. HPLC chromatograms of the O,N-acyl migration of peptide 9 at 37°C, pH 7.4. 
The appearance of a new peak (Son) on the HPLC chromatogram is associated with triggering of 
both switches simultaneously.  The half-time value for migration in peptide 9 (25 min) was 
found to be similar as in peptide 8. However, unlike peptide 8, pH triggering of peptide 9 at a 
concentration of 20 µM did not result in the formation of fibrils, and CD spectra indicated a 
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predominant random coil structure after 5 hours of incubation at 37°C; in addition, only a weak 
Th T fluorescence signal was observed. This result prompted us to carry out the following 
experimental analyses at increased peptide concentrations; i.e. c = 40 µM.  
 
Figure 55. CD monitoring of the conformational transition of peptide 9 from random coil to β-sheet 
conformation at physiological conditions. 
 
The CD spectra (Figure 55) show that incubation of peptide 9 (40µM) at pH 7.4 results in a 
complete conversion from random coil to β-sheet structure within 4.5 hours. pH-induced changes 
in secondary structure of peptide 9 appeared slow within the first hour, showing a predominantly 
random coiled structure by CD, in agreement with the oligomeric morphology found by EM 
(Figure 56).  The presence of fibrils and the onset in β-sheet formation was found after 2.5 hours 
of incubation, which seemed to be complete after 4.5 hours. A similar trend of increase in ThT 
fluorescence was observed, showing low levels ThT binding in peptide 9 within the first hour of 
incubation (Figure 57). The CD spectra revealed an isosbestic point for t = 1h, 2h30, 3h, 4h30 
suggesting a two-state transition within this time frame.   
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Figure 56. kinetic of fibril formation of peptide 9 followed by electron microscopy.  
 
 
 
 
Figure 57. Bar chart representing the ThT values of peptide 9 incubated at 40 µM under physiological 
conditions. 
In conclusion peptide 9 transforms from a soluble, flexible, unfolded state (Soff) in situ to a β-
sheet structure as monitored by CD spectroscopy, EM, and ThT fluorescence studies. Similar to 
peptide 8, we further probed the potential of this model for mimicking Aβ folding and 
aggregation and for examining the impact of three molecules well-known for their Aβ fibril-
destabilizing activity upon the onset of ordered conformations during the process of structure 
evolution (“in statu nascendi”).  
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Screening of molecules of Aβ fibril-destabilizing activity 
 
Aggregation kinetics in the presence of tannic acid, myricetin or dopamine were investigated 
using ThT fluorescence measurements and Electron Microscopy. 
 
Experiments 
Peptide 9 was dissolved in H20 to a final concentration of 800 µM (stock solution). The solution 
was vortexed for 30 seconds and filtered through a 0.2 µm filter by centrifugation (5 min at 
10’000 rpm). 50 µL aliquots of the filtrate were put into autoclaved Eppendorf tubes. 750 µL of 
100 µM acetate buffer, pH 4.6 were added to each tube. The inhibitors were dissolved in MeOH 
at concentrations of 400 to 800 µM and 100 µL of these stock solutions were added to the 
mixture to give the correct final concentration of inhibitor in the reaction mixture. 100 µL of Tris 
buffer pH 7.4 (0.3 M + 150 mM NaCl) were added to each vial to trigger the acyl migration and 
placed at 37°C for 48 hours. Aliquots of 90 µL were removed from the incubated samples at 
different time points and stored at -18°C until further analysis. 
 
ThT and EM analysis 
By incubating peptide 9 at 37°C, ThT fluorescence followed a characteristic hyperbolic curve, 
pointing to a fast nucleation. This curve is consistent with a first-order kinetic model observed by 
Naiki and Nakakuki. When peptide 9 was incubated with 80 µM tannic acid, myricetin or 
oxidized dopamine, the final equilibrium level decreased significantly indicating that no fibrils 
were present in the mixture. A low signal was also observed for the Soff state of 9 (at 48h), 
indicating the presence of random coil conformation.  
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Figure 58. Kinetics of fibril formation monitored by Th T fluorescence. Control (green); after addition of 
80 µM tannic acid (blue), 80 µM myricetin (cyan) and 80 µM dopamine (back), control peptide in the Soff 
state (red). 
EM data are in support of the results obtained by ThT analysis. Most notably, we observe after 
two days incubation that peptide 9 forms mature amyloid-like fibrils (Figure 59, A), whereas 
when incubated in the presence of inhibitors no fibrils were present in the solution; only 
amorphous aggregates were observed by EM. In addition, incubation at pH 4.6 (Soff  state) did 
not result in amyloid-like fibrils, in agreement with the adoption a soluble, unordered 
conformation in the Soff state over days at 37°C; short, non amyloid-like fibrils in the sample can 
be rationalized by ester bond hydrolysis (ca 5% after 48 h at 37°C, see Figure 22). 
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Figure 59. EM images of peptide 9 after 48 h at 37°C and pH 7.4 A) control Son state, B) tannic acid 2 eq, 
C) myricetin 2 eq, D) oxidized dopamine 2 eq, E) control peptide 9 in the Soff state. 
To probe the impact of an inhibitor upon the kinetics of acyl migration, peptide 9 was subject to 
O,N-acyl migration in the presence of tannic acid as monitored by HPLC. As shown in Figure 60 
the migration occurs reaction proceeds without any disturbing effect by the inhibitor. The mass 
of the Soff and Son peak being identical, the more hydrophilic peak (Rt = 18.1 min) could be 
attributed (MALDI-TOF) to the peptide in the Soff state. 
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Figure 60. HPLC monitoring of the O to N acyl migration of peptide 9 (c = 40 µM) in presence of 2 eq 
tannic acid inhibitor (see text). 
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4.3. Discussion 
 
We have demonstrated that the host guest technique combined with the switch concept represent 
a versatile tool to follow the folding and aggregation of the sequence Aβ (14-24), which plays a 
key role in β-sheet nucleation of full-length Aβ. Our results suggest that starting from a stable, 
unfolded state (Soff), the self-assembly and β-sheet formation as molecular origin of peptide 
fibrillogenesis can be studied in situ using specific nucleation sites of native Aβ as guest 
segments within a host model peptide. EM and CD data indicate that the kinetics of the onset of 
fibril formation of both peptide 8 and 9 is fast and that the aggregates formed are similar to those 
by native Aβ(1-42). The designed host guest systems, i.e. Aβ (14-24) flanked N- and C-
terminally by (Leu-Ser)n oligomers proved to be a versatile model of amyloid β for studying the 
onset of β-structures and subsequent fibrillogenesis. 
Moreover, we have validated the host guest approach as a convenient and reliable screening 
system for the investigation of molecules of Aβ fibril destabilizing activity. 
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5. Design and synthesis of Switch-peptides of amyloid β  fibril disrupting 
potential 
5.1. Background 
 
The main targets for therapeutic intervention of the Aβ cascade include the inhibition of Aβ 
production, the inhibition of Aβ aggregation and fibril formation, in addition to the inhibition of 
the consequent inflammatory responses caused by the Aβ deposition. 
Soto et al., Tjenberg et al. as well as Kapurniotu et al. proposed that short synthetic peptides 
capable of binding Aβ but unable to become part of the β-sheet structure (β-sheet breaker 
peptides) may stabilize the amyloidogenic Aβ conformer and hence preclude amyloid 
formation123-126. Thus, these peptides have the ability to interact specifically with Aβ and block 
its β-sheet conformation, to disassemble preformed fibrils in vitro, to prevent neuronal death 
induced by fibrils in cell culture, to reduce amyloid β-protein deposition in vivo and to block the 
formation of amyloid fibrils in a rat brain model of amyloidosis. However, this hypothesis of β-
breaking might have a counterproductive effect by transforming fibrils to oligomeric structures 
that are nowadays thought to be the most toxic species in the pathology of AD. At present, 
although some efficient drugs in slowing down the symptoms exist and huge progress are being 
made, there is still no effective treatment available for AD as well as for most of the protein 
folding disorders. However, the 5-residues peptides (Ac-LPFFD-NH2 and Ac-LP(NMe)FFD-
NH2) proposed by Soto protected at his N- and C-termini to prevent proteolytic degradation and 
to increase its blood-brain barrier permeability have shown the potential to be used as therapeutic 
agents to prevent or retard the progression of amyloidosis in AD125.  
To further increase their stability and breaking effects, various pseudoprolines (ΨPro) were 
substituted for Pro. Ψ-Pro are Ser, Thr or Cys-derived proline analogs. For example, the Pro-
specific induction of the cis-geometry127 of the Xaa-ΨPro imide bond is pronounced and as a 
non-natural amino acid, it is more stable against proteolytic degradation. 
The two pseudoproline-containing peptides investigated by Soto and Mutter et al. showed good 
enzymatic stability but a lower fibril inhibition activity compared to the Pro containing 
analogues72. The stabilization of the cis-configuration reduced the inhibition activity of the 
peptides suggesting, as the cis-Pro is the active conformation, that the trans-Pro is required for 
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binding to the target. It seems that conformational flexibility of the molecules is, at least in the 
recognition/binding step, crucial for activity. The process of fibrillogenesis inhibition can be 
delineated as two distinct steps: first, the peptides recognize a particular stretch of the Aβ 
sequence and second, upon binding lead to a conformational destabilization of β-sheet structure 
formation. In the first step, the constraint (the cis amide bond) imposed by the pseudo-proline 
results in reduced binding to the Aβ of the β-sheet breaker peptides. Consequently, it seemed 
reasonable to separate structure from function by using switch-peptides.  
For this purpose, we have designed switch-peptides comprising a recognition element (P2) and a 
ΨPro-derived β-disrupting unit (P1) separated from each other by a switch element (S) (Figure 
61). Upon introduction of a flexible ester-bond, the impact of the ΨPro-moiety is decoupled from 
the peptide chain and does not interfere with the bonding properties of the recognition sequence. 
After binding of the peptide to the Aβ sequence, the switch can be triggered and the β-sheet 
destabilizing effect of the ΨPro is initiated. Thus, the modular character of switch-peptides is 
ideal to take into account the dual action of β-strand recognition/binding and β-sheet 
desabilization (Figure 61). 
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Figure 61. Disruption of β-sheets with kink-inducing switch-peptides. 
5.2. Design and synthesis 
 
Five different switch-peptides containing either the dimethyl-pseudo-proline or the dihydro-
pseudo-proline in the β-sheet destabilization unit P1 were designed. The recognition sequence P2 
was either H-Phe-Phe-Asp-NH2 or H-MePhe-Phe-Asp-NH2. The switch element was protected 
either by a proton (H+) or a dipeptide (ArgPro), cleavable by the enzyme DPPIV. Scheme 5 
gives a general overview of the different switch-peptides synthesized and further investigated.  
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18: R = H, R' = Me, Y = H
19: R = Me, R' = Me, Y = ArgPro
R'
Ac-Leu-Cys(!R,Rpro)- Ala-(Y)Ser- (NR')-Phe-Phe-Asp-NH2  
Scheme 5. General scheme of Amyloid-derived switch-peptides (see text). 
 
Firstly, pseudoproline derivatives were synthesized from cysteine hydrocloride and 
subsequently, the building block Ac-Leu-Cys(ψR, R)pro-OH was prepared (see Figure 62) for 
further incorporation in solid phase peptide synthesis. 
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Figure 62. Synthesis of the dipeptide Ac-Leu-Cys(ψR, Rpro)-OH. (i) sol. HCHO 40% / H2O (4/10), 
overnight, RT, quantitative; (ii) acetone/dimethoxypropane (80/18), reflux, 2h, quantitative, (iii) DAST 
(1.2 eq), DCM, 15 min, (iv) Dipea (2 eq), DCM, 1h, 30%. 
The synthesis of the five switch-peptides were performed on a Sieber amide resin (loading 0.71 
mmol/g) following the Fmoc/tBu strategy as depicted in Scheme 6  
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resin: Sieber Amide Fmoc(NR)PhePheAsp(OTBu)
Boc-HN-Ser(NR)PhePheAsp(OTBu)
HO
Boc-HN-Ser(NR)PhePheAsp(OTBu)
FmocAlaO
Boc-HN-Ser(NR)PhePheAsp(OTBu)
AcLeuCys(! R,R)proAlaO
i
ii
iv
AcLeuCys(! R,R)proAlaO
AcLeuCys(! R,R)proAlaO
Boc-HN-Ser(NR)PhePheAsp(OTbu)-NH2
H+-Ser(NR)PhePheAsp(OH)-NH2
iii
v
vi
vii
Fmoc-HN-Ser(NR)PhePheAsp(OTBu)
HO
i
(Boc)Arg(diBoc)Pro-HN-Ser(NR)PhePheAsp(OTBu)
HO
iv
(Boc)Arg(diBoc)Pro-HN-Ser(NR)PhePheAsp(OTBu)
FmocAlaO
(Boc)Arg(diBoc)Pro-HN-Ser(NR)PhePheAsp(OTBu)
AcLeuCys(! R,R)proAlaO
AcLeuCys(! R,R)proAlaO
AcLeuCys(! R,R)proAlaO
(Boc)Arg(diBoc)Pro-HN-Ser(NR)PhePheAsp(OTbu)-NH2
ArgPro-Ser(NR)PhePheAsp(OH)-NH2
v
vi
vii
 
Scheme 6. Solid phase synthesis of β-breaker switch-peptides 15 to 19. Resin Sieber amide (0.71 
mmole/g), (i) PyBop (2 eq), aa (2 eq), Dipea (4 eq), (ii) Boc-Ser-OH ( 2 eq), HATU (2 eq), Dipea (4 eq), 
(iii) Fmoc-Ser-OH (2 eq), HATU (2 eq), Dipea (4 eq), (iv) DIC (3 eq), DMAP (0.1 eq), Fmoc-Ala-OH (3 
eq), (v) AcLeuCys(ψR, R)pro-OH (2 eq), HATU (2 eq), Dipea (4 eq), (vi) resin cleavage 1% TFA in DCM 
2x20 min, (vii) Boc and tBu cleavage: 50% TFA in DCM, 2.5% TIS and 2.5% H2O. 
The syntheses were straightforward and gave after purification by preparative HPLC a white 
powder with 15% to 20 % yield depending on the peptide (see experimental part). Here is the list 
of the switch-peptides synthesized followed by their analytical data: 
Peptide 15: Ac-Leu-Cys(ψMe, Mepro)-Ala-(H+)Ser-Phe-Phe-Asp-NH2 
Peptide 16: Ac-Leu-Cys(ψH, Hpro)-Ala-(H+)Ser-Phe-Phe-Asp-NH2 
Peptide 17: Ac-Leu-Cys(ψMe, Mepro)-Ala-(H+)Ser-(NMe)Phe-Phe-Asp-NH2 
Peptide 18: Ac-Leu-Cys(ψH, Hpro)-Ala-(H+)Ser-(NMe)Phe-Phe-Asp-NH2 
Pepitde 19: Ac-Leu-Cys(ψMe, Mepro)-Ala-(ArgPro)Ser-(NMe)Phe-Phe-Asp-NH2 
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 Analytical HPLC of purified compound ES/MS of purified compound 
15 
  
16 
  
17 
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18 
  
19 
  
Figure 63. Analytical data of the purified compounds. HPLC (C18, gradient 0 to 100% A, 30 min); Mass 
spectroscopy ESI-MS. 
5.3. Kinetic studies  
5.3.1. pH-induced acyl migration  
Peptide 15: Ac-Leu-Cys(ψMe, Mepro)-Ala-(H+)Ser-Phe-Phe-Asp-NH2  
 
To assess the influence of pH on the migration speed, the acyl migration of peptide 15 were 
triggered at three different pH (pH 6, 6.6 and 7.4). All experiments were done at 37°C, the 
peptide was dissolved in a mixture of acetonitrile/phosphate buffer of the desired pH (1:9) to a 
final concentration of 500 µM. At different time points, 20 µL aliquots were removed, quenched 
with 20 µL HCl 1 M and injected to analytical HPLC.  
Figure 64 below shows the HPLC chromatograms of the migration at pH 6. The HPLC shows 
two peaks at Rt = 17 min corresponding to the Soff state and Rt = 20 min (Son state after O to N 
migration). Upon migration, we observe the decrease in absorbance of the Soff peak and the 
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increase of the Son peak; the migration is relatively rapid, even at pH 6 since the half-life value is 
about 25 min (see Figure 65).  
 
 
Figure 64. HPLC chromatograms of the O to N acyl migration of peptide 15 in buffer pH 6/acetonitrile 
(9:1) 
For the three different assays, the percent of peptide in the Son state was plotted against time to 
compare the influence of the pH on acyl migration speed.  
 
Abs 
time (min) 
conversion 
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Figure 65. Overlay of time course and pseudo-first order kinetics of switch-peptide 15 subjected to 
different pH conditions. 
The results obtained here at different pH show that the migration is extremely sensitive to pH. At 
pH 7.4 the half-life value was only of 1.5 min and at pH 6 was of 24 min, it is thus easier to 
follow the migration by HPLC at pH 6. Peptides 16, 17 and 18 were therefore investigated at pH 
6 under similar conditions. 
 
Peptide 16 : Ac-Leu-Cys(ψH, Hpro)-Ala-(H+)Ser-Phe-Phe-Asp-NH2 
peptide 16 was dissolved in phosphate buffer pH 6 containing 10 % acetonitrile to a final 
concentration of 500 µM. Figure 66 shows the chemical conversion of the peptide from its Soff 
state to its Son state. In these conditions, the half-life value of the peptide (Soff state) is about 14 
min (Figure 67). We also observe that the migration is complete after 90 min. 
 
 
Figure 66. HPLC chromatograms of the O to N acyl migration of peptide 16 in buffer pH 6/acetonitrile. 
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Figure 67. pH-induced acyl migration: time course (pink: Son, blue: Soff) and pseudo-first order kinetics 
of peptide 16. 
These results indicate that peptide 16 containing a dihydro-pseudoproline rearranges faster than 
peptide 15 containing a dimethyl-pseudoproline. This can be explained by the steric constraints 
imposed by the methyl groups of the dimethylpseudoproline and by the difference in 
electronegativity of the two pseudoprolines. 
Peptide 17: Ac-Leu-Cys(ψMe, Mepro)-Ala-(H+)Ser-(NMe)Phe-Phe-Asp-NH2 
O to N acyl migration of peptide 17 was followed under similar conditions as previously. We 
observe here that the half-life value is about 19 min; it was of 25 min in the case of peptide 15 
(Figure 68 & Figure 69). Compared to peptide 15, peptide 17 also contains a dimethyl-
pseudoproline but possesses an N-methylated phenylalanine after the S element. Interestingly, 
the constraint imposed by the methyl groups of the pseudo-proline has the effect of retarding the 
O,N-acyl migration (see results above) but on the contrary, the N-methylation of the residue Phe 
succeeding the switch element facilitates and accelerates the migration. One plausible 
explanation to this fact is that the methyl group of the N-methyled Phe residue, more 
electronegative than hydrogen, attracts electrons towards itself and speed up the migration by 
dislocating the electrons in the same direction as the O, N-acyl migration, contrary to dimethyl-
pseudoproline (on the left side of the switch element) attracting the electrons on the opposite 
direction and hence having the effect of retarding the migration. 
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Figure 68. HPLC chromatograms of the O to N acyl migration of peptide 17 in buffer pH 6/acetonitrile. 
 
Figure 69. pH-induced acyl migration: time course (blue: Son, pink: Soff) and pseudo-first order kinetics 
of peptide 17. 
Peptide 18: Ac-Leu-Cys(ψH, Hpro)-Ala-(H+)Ser-(NMe)Phe-Phe-Asp-NH2  
Peptide 18 containing a dihydro-pseudoproline and a N-methylated phenylalanine after the 
switch element had the fastest rearrangement time under the conditions used for peptides 15, 16 
and 17. Indeed, its half-life rearrangement value is of 8 min only (Figure 71), which is 3 times 
faster than peptide 15 having a dimethyl-pseudoproline and no N-methylation of the 
phenylalanine. This is easily explained by the reasons given earlier in this chapter. 
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Figure 70. HPLC chromatograms of the pH induced acyl migration of peptide 18 at pH 6.  
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Figure 71. pH-induced acyl migration: time course and first order kinetics of switch-peptide 18. 
In summary, it emerges from these studies that O,N-acyl migration is greatly influenced by the 
pH. The half-life value can go from 1.5 min at pH 7.4 to 24 min at pH 6 (which means a factor of 
12). The results obtained also point out that modifications brought to the molecule, even small, 
can have an impact on the kinetic of migration.  
5.3.2. O to N acyl migration induced by enzymatic triggering  
Peptide 19: Ac-Leu-Cys(ψMe, Mepro)-Ala-(ArgPro)Ser-(NMe)Phe-Phe-Asp-NH2 
The enzymatic conversion of peptide 19 was performed under physiological conditions. The 
peptide was dissolved in PBS pH 7.4 buffer at a concentration of 500 µM and incubated at 37° 
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with DPPIV enzyme (ratio enzyme/substrat: 1/25 000). The enzymatic cleavage and the 
migration were monitored by analytical HPLC. At different time points, 20 µL aliquots were 
withdrawn and injected to HPLC. Figure 72 shows the HPLC chromatograms of the enzymatic 
triggering of peptide 19.  
 
 
 
Figure 72. HPLC chromatograms of the enzymatic cleavage of dipeptide H-Arg-Pro-OH from switch-
peptide 19 (Soff), and subsequent acyl migration to give 19 in the Son state. 
HPLC overlay (Figure 72) shows the appearance of a first very hydrophilic peak corresponding 
to the cleavage of H-Arg-Pro-OH dipeptide by the enzyme. A second peak, decreasing with time, 
corresponds to the peptide in the Soff state. A third peak corresponding to the Soff state after Arg-
Pro cleavage but before acyl migration is observed and eventually, a fourth peak corresponding 
to the peptide in its Son conformation appears with a higher retention time. The enzymatic 
cleavage is relatively rapid; the conversion is complete after 2 hours 15 min at pH 7.4 (t1/2 ≈ 20 
min). It is, however, slower than pH triggered acyl-migration for which a half-life value of 1.5 
min was observed at pH 7.4.  
5.4. Study of the inhibition potential of Amyloid-derived switch-peptides  
The inhibition potential of the five switch-peptides on fibrillogenesis was evaluated at 
physiological conditions by two different methods, electron microscopy and thioflavin T 
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fluorescence on host-guest switch-peptide 9, which proved to be a powerful tool for the 
screening of potential inhibitors of fibril formation in the previous section (see section 4).  
 
Experminental procedure 
 
Host-guest switch-peptide 9 was dissolved in H20 to a final concentration of 800 µM (stock 
solution). The solution was vortexed for 30 seconds and filtered through a 0.2 µm filter by 
centrifugation (5 min at 10’000 rpm). 50 µL aliquots of the filtrate were put into autoclaved 
Eppendorf tubes. 750 µL of acetate buffer pH 4.6 100 µM were added to each tube. The 
inhibitors were dissolved in MeOH at concentrations of 1.6 mM and 100 µL of these stock 
solutions were added to the mixture to give the correct final concentration of inhibitor in the 
reaction mixture. After 30 min (recognition lag time), 100 µL of Tris buffer pH 7.4 (0.3 M) and 
150 mM NaCl were added to each vial to trigger the switch. They were then placed in a 37°C 
water bath for 48 hours. Aliquots of 90 µL were removed from the incubated samples at different 
time points and stored at -18°C until further analysis. 
 
ThT and EM analysis 
When peptide 9 was incubated alone at 37°C for 48 h, its ThT fluorescence curve  (Figure 73, 
black curve) was similar to the ThT fluorescence curve of the full length Aβ121 (not shown). EM 
images taken after 2 days revealed amyloid-like fibril formation, confirming the results obtained 
from ThT measurements.  
 
Chapter II  Results & Discussion 
 
 95 
 
Figure 73. Kinetics of fibril formation of peptide 9 (40 µM) monitored by ThT fluorescence. Control 
(black), with 160 µM of peptides 15 (red), 16 (green), 17 (blue), 18 (cyan), and 19 (pink). 
Figure 73 and Figure 74 (E) show that peptide 18 for which O,N-acyl migration was the fastest 
seems to have no inhibitory effect on fibril formation. Other inhibitors activated by pH with 
longer t1/2 half-life values showed a slightly increased inhibition (about 22% of inhibition by ThT 
after 48h). We can see by EM that the fibrils formed when peptide 9 is incubated in the presence 
of inhibitors 15, 16, 17 and 19 are shorter than fibrils of the control sample (see Figure 74). 
Interestingly, peptide 19, which is activated by the enzyme DPPIV, exhibited a better inhibitory 
effect compared to the other investigated compounds (about 47% of inhibition after 48h). This 
phenomenon had previously been observed 104,128 and can be explained by the fact that O,N-acyl 
migration of peptides activated by enzymes is slower because enzyme triggering is the rate 
limiting step for acyl migration and not rearrangement. The results confirm previous 
observations that the switch-peptide in its Soff state where the recognition sequence of Aβ is 
separated from the kink inducing unit should have time to first recognize Aβ sequence before 
setting off the kink structure that stabilizes fibrils. 
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Figure 74. EM images of peptide 9 after 48 h at 37°C and pH 7.4, A) alone and in presence of 4 
equivalents of B) peptide 15, C) peptide 16, D) peptide 17, E) peptide 18 and F) peptide 19. 
To compare the inhibitory effect of our molecules with the well-known pentapeptide inhibitor 
iAβ5 (Ac-LPFFD-NH2) and with Ac-LVFFD-NH2, their inhibitory effect was tested on peptide 9 
under the same conditions as above. ThT fluorescence of peptide 9 with 4 eq of inhibitors did not 
show any decrease in fluorescence compared to the control.  
 
Figure 75. Kinetics of fibril formation of peptide 9 (40 µM) monitored by ThT fluorescence. Control 
(green), with 160 µM of Ac-LVFFD-NH2 (red), Ac-LPFFD-NH2 (black). 
Chapter II  Results & Discussion 
 
 97 
However, although fibrils were observed by EM, they were shorter than the fibrils observed for 
the control. From these studies, we deduce that both molecules had a smaller inhibitory effect on 
peptide 9 fibrillogenesis than switch-peptides molecules investigated earlier. This confirms 
previous observations that the introduction of a switch element separating the β-sheet breaking 
unit from the recognition sequence enable a better recognition of the target before activating the 
switch, restoring the regular amide backbone and setting off the β-disrupting unit activity. This 
sequential process allows the peptide to be in closer contact with the target and have a stronger 
impact on fibril destabilization.  
 
Figure 76. EM images of peptide 9 after 48 h at 37°C and pH 7.4, A) alone and in presence of 4 
equivalents of B) Ac-LVFFD-NH2, C) Ac-LPFFD-NH2. 
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5.5. Discussion 
 
The switch-peptides were successfully synthesized by SPPS in good yields. It emerges from 
these studies that O,N-acyl migration is greatly influenced by the pH. The half-life value can go 
from 1.5 min at pH 7.4 to 24 min at pH 6 (which means a factor of 12). The results obtained also 
point out that modifications brought to the molecule, even small, can have an impact on the 
kinetic of migration. 
No significant differences in term of inhibition potential were noted between the switch-peptides 
triggered via pH, except for peptide 18 having the fastest rearrangement half-time value. The 
peptide did not show any inhibitory activity. The major reason might be that the peptide does not 
stay long enough in its recognition state (Soff state) before rearranging and thus, does not bind 
correctly to the target sequence to block its β-sheet and fibril formation.  
Moreover, the rearrangement of switch-peptide 19 having a protecting group cleavable by an 
enzyme was slower and could be controlled easily. Peptide 19 was able to stay longer in the Soff 
state for better recognition, which was beneficial since it exhibited better inhibition activity 
compared to other peptides triggered via pH (47% inhibition vs. 22% inhibition).  
Compared to the two pentapeptides Ac-LVFFD-NH2 and Ac-LPFFD-NH2 tested in the same 
manner, the switch-peptides had an enhanced inhibitory activity on the fibril formation of host-
guest switch-peptide 9.  
These results open interesting perspective in the rational design of flexible peptides able to bind 
β-sheets in an efficient way before setting off the kink in situ, increasing the biological potential 
of inhibitors. 
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6. Disruption of Amyloid-Derived Peptide Assemblies through the Controlled 
Induction of a β-sheet to α-Helix Transformation: Application of the 
Switch-Concept2 
 
Protein misfolding and self-assembly into highly ordered β-sheet rich fibrillar assemblies known 
as amyloid fibrils are common features of a growing class of systemic and neurodegenerative 
diseases, including Alzheimer’s, Parkinson’s, Huntington’s disease, senile systemic amyloidoses, 
and type II diabetes129, 130. Although there is strong evidence implicating amyloid formation in 
the pathogenesis of these diseases, the precise mechanisms of amyloid formation and clearance 
in vivo as well as the structural basis of amyloid toxicity remain unknown. The lack of tools to 
monitor and/or control the initial structural transitions associated with protein misfolding, 
amyloid formation and/or dissociation is at the origin of this gap in knowledge. Significant 
efforts have been devoted to study proteins and small peptides that self-assemble into amyloid-
like fibrillar structures as model systems to investigate amyloid formation or to generate 
materials with interesting physical properties. However, our knowledge of the mechanical and 
structural dynamics within β-sheet assemblies such as amyloid fibrils remains limited. Early 
assumptions131 that β-sheet assemblies, including amyloid fibrils, occupy a global minimum of 
free energy that is lower than that of the native state led to greater emphasis on understanding 
and inhibiting amyloid formation, rather than amyloid dissociation and clearance. Despite the 
extreme stability of β-sheet rich amyloid fibrils to proteases, acid and chemical denaturants, 
increasing evidence from humans132 and in vitro studies points to a dynamic structure within 
amyloid fibrils and suggests that the process of amyloid formation is reversible133, 134.  These 
findings combined with the fact that strategies aimed at destabilizing amyloid and/or accelerating 
their clearance seem to reverse the disease phenotype135-137 suggest that a detailed understanding 
of the stability and dynamic behavior of amyloid fibrils is of critical importance to developing 
therapeutic strategies for amyloid diseases. 
Our laboratory has previously shown80, 100, 112 that incorporation of molecular switches into 
polypeptides, based on ON intramolecular acyl migration in situ105, 106, 138, 139, allows for 
                                                
2 This Chapter has been published in Angew. Chem. Int. Ed, 2007, 46, 2681-2684 
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controlled induction or reversal of secondary structural transitions140-142 and self-assembly of 
small peptides.  
Moreover, during his PhD Thesis143, R. Mimna, who worked mainly on the design and synthesis 
of helix-inducing N-cap compounds (σ)144, was able to demonstrate that in model switch-
peptides, N-cap units prevented the formation of β-sheet by inducing a stable α-helical structure. 
Subsequently, an amyloid-derived switch-peptide containing an N-cap as conformational 
induction unit (σ) was designed. By triggering the switch, we could observed a transformation of 
type β to α by Circular Dichroism (CD). Based on these primarily findings, the work presented 
in this chapter focuses on further investigating the feasablilty of disrupting amyloid formation 
through the controlled induced transformation form β-sheet to α-helix structures of the self-
assembled peptides within the amyloid structure (Figure 77). 
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6.1. Design 
 
 
Figure 77. Aβ(14-25) is linked to a helix-inducing template σ (Ncap = Ac-[cyclo-1-5]-KARADA) through 
a Ser-derived switch-element S (O-acyl isopeptide unit, Soff-state). On removal of the N-protecting group 
Y, spontaneous O,N-acyl migration occurs (Son state) resulting in the activation of σ  and induction of a 
helix structure in peptide 7 (left). Under the right conditions, the helix-nucleating effect of σ  is strong 
enough to induce a transformation from β-sheet (step 1) to α-helix (step 2), along with disruption of the 
preformed Aβ(1-42)-derived β-sheet-rich assemblies within amyloid fibrils. 
The amyloid-derived switch-peptide contains the shortest Aβ fibril-forming sequence 
HQKLVFFAEDVG, corresponding to Aβ(14-25), connected to a helix nucleating Ncap144 (σ) 
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via a Ser-derived switch element (S) (Peptide 7, Figure 77). The Aβ(14-25) peptide contains the 
amino acid residues 16-20 that are essential for fibril formation in the full length Aβ peptide and 
readily forms amyloid fribrils in vitro145, 146. As Ncap, we chose the cyclic pentapeptide sequence 
Ac-(cyclo-1-5)-KARAD, which contains a lactam bridge formed between the Lys and Asp 
residues at positions i and i + 4 respectively144. This type of lactam bridge effectively constrains 
the residues into an enforced α-helical turn and, when incorporated into a larger peptide, can 
greatly increase the overall helicity147, 148. 
6.2. Synthesis  
 
The synthesis of peptide 7 was performed in collaboration with R. Mimna (PhD Thesis 2005, 
EPFL). The fibril-forming peptide Aβ(14-25), HQKLVFFAEDVG, was assembled on Rink 
amide resin (0.60 mmol/g, 0.30 g, 0.18 mmol), using standard Fmoc-based solid-phase 
synthesis149. The switch-element was introduced by manually coupling the protected 
depsidipeptide Fmoc-Ala-(Boc)Ser-OH150 as described by Coin et al.139. Subsequently, the N-
capping template was introduced as protected building block Fmoc-(cyclo-1-5)-KAR(Pbf)AD-
OH140-142. Cleavage from the resin and purification by semi-preparative HPLC afforded peptide 
7, Ac-[(cyclo-1-5)-KARAD]A-S1-HQKLVFFAEDVG-NH2 (S1 = (+H)Ser)150, as a white powder 
and was characterized by analytical HPLC (> 95% purity) and ESI-MS (1056.86 [M + 2H/2]+, 
704.81 [M + 3H/3]+, 529.31 [M + 4H/4]+). 
 
Scheme 7.  Synthesis of switch-peptide 7.  (i) standard Fmoc/tBu SPPS;  (ii) dipeptide Fmoc-Ala-
(Boc)Ser-OBzl (2.5 eq), PyBOP (2.5eq), DIEA (5eq), DMF, 1.5h;  20% piperidine/DMF, 10 min x 2;   
(iii) Fmoc-(cyclo-1-5)-KAR(Pbf)AD-OH  (2 eq), PyBOP (2 eq), DIEA (4 eq), DMF, 2h;   20% 
H2N
Rink amide resin
(i)
HQKLVFFAEDVG
(ii)
A-S1-HQKLVFFAEDVG
Boc
(iii)
Ac-KARADA-S1-HQKLVFFAEDVG
Boc
N-cap A!(14-24)
switch element
Ac-KARADA-S1-HQKLVFFAEDVG-NH2
S1 = (
+H)Ser
N-capped A! switch peptide 7
(iv)
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piperidine/DMF, 10 min x 2;  Ac2O (10 eq), pyridine (10 eq), DMF, 30 min;  (iv) TFA/TIS/H2O/DODT 
95/2/2/1, 2h. 
 
 
 
Figure 78.  Analytical data of switch-peptide 7 a) HPLC chromatogram of crude compound, b) HPLC 
and ESI-MS (inset) of purified compound. 
 
6.3. N-cap induced β to α  reversal of Aβ(14-25) 
 
CD and EM studies 
 
To examine the solution properties of peptide 7 in the Soff and Son states (Figure 77), the 
secondary structure and aggregation state of the peptide was probed by circular dichroism (CD) 
and electron microscopy (EM).  
In the Soff state (pH 4.5, 50 mM acetate, 150 mM NaCl) and at concentrations between 10-100 
µM, peptide 7 displays a CD spectra showing the typical cotton effect of a β-sheet structure 
(curve 1 in Figure 79). Activation of the helix-inducing Ncap (Son) via a pH–induced O,N-acyl 
migration80, 100, 105, 106, 138, 139 is not sufficiently strong to overcome the intrinsic β-sheet 
propensity of Aβ(14-24) resulting in identical CD spectra. However, when activated in the 
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presence of 25% TFE as α-helix promoting cosolvent, an unprecedented structural transition 
from predominantly β-sheet in the Soff state with a strong negative cotton effect a λ = 218 nm 
(curve 2) to an α-helix in the Son state with negative cotton effects at λ = 204 nm and 222 nm 
(curve 3) is observed and is complete within less than 5 min at room temperature (t1/2 value = 
150 sec, Figure 79, inset). This result demonstrates the strong nucleating effect of the Ncap and 
shows for the first time the possible reversibility of highly ordered β-sheet structures.   
 
Figure 79. Conformational transitions of peptide 7 (c = 5 x 10-5 M, T = 25°C) : A) curve 1: pH 4.6 buffer 
(Soff); curve 2: pH 4.6 buffer/TFE 75:25 (Soff); curve 3: pH 7.0 buffer/TFE 75:25 (Son). Inset: the kinetics 
of the conformation from β-sheet (Soff) to α-helix (Son) structures as monitored by changes in the CD 
signal. 
 
 
Figure 80. Negative electron micrographs of peptide 7 (c = 5 x 10-5 M) in the Soff state (A) and Son state 
5min (B) and 12 h (C) after activation of the intramolecular O to N acyl migration. 
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Electron microscopy (EM) studies revealed that the transition from β-sheet to α-helical structure 
is accompanied by a dramatic change in the morphology of the fibrils and subsequent 
dissociation.  Figure 80 shows negatively stained micrographs of peptide 7 before (Soff, A) and 
after (Son, B and C) triggering the switch element in the presence of 25% TFE. In the Soff state, 
peptide 7 self-assembles into long (> 2 µm) unbranched fibrils with an average diameter of 3.3 
nm (Figure 9A, inset: a). Lateral association of these thin fibrils results in the formation of 
twisted amyloid-like fibrils with an average diameter of 7.7 nm, 11 nm, and 20 nm, consistent 
with the 3.3 nm being the subunit “protofilament” of the wider fibrils (Figure 9A). Interestingly, 
upon triggering the O,N-acyl migration (Son state), short ribbon-like structures (Figure 80B) are 
observed, but disappear quickly with time giving rise to predominantly soluble α-helical 
structures of peptide 7.  Filtration of peptide 7 solution (Soff state) through a 0.22 µm membrane 
results in the loss of more than 80% of the peptide and disappearance of β-sheet structure (see 
Figure 80). In the Son state, more than 95% of peptide 7 remains in solution after filtration 
through 0.22 µm membrane, consistent with the transition from an aggregated β-sheet to soluble 
α-helix structures (CD)(Figure 81) as evidenced by the disappearance of fibrillar assemblies 
(Figure 80C), and loss of ThT fluorescence upon activation of the O,N-acyl migration (Figure 
82).   
 
Figure 81. CD spectra of peptide 7 in the Son state in 25% TFE at 25°C of the filtrate after filtration 
through a 10kDa membrane filter (dashed line), and of the retentate (continuous line). 
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Thioflavin T (ThT) and Congo Red (CR) binding of peptide 7 
 
To confirm our results on the morphology of the fibrils, peptide 7 was mixed with amyloid 
specific dyes such as Congro Red (CR) and Thioflavin T (ThT) and its binding to these dyes was 
assessed by UV spectroscopy and fluorescence sperctroscopy respectively (Figure 82). 
The binding of peptide 7 to the amyloid specific dye Congo Red (CR) causes a red-shift in its 
absorbance spectrum, characteristic of amyloid fibrils. The left part of Figure 82 shows the 
absorbance spectra of Congo Red alone (full line), in the presence of peptide 7 in the Soff -state 
(dashed line) or preformed α-synuclein fibrils (dotted line).  The CR spectrum in the presence of 
peptide 7 resembles those previously published for Aβ and is virtually identical to that observed 
for preformed fibrillar assemblies of the amyloid forming protein α-synuclein linked to 
Parkinson’s disease.  Amyloid fibrils of α-synuclein were used because a freshly prepared 
fibrillar sample was available at the day the experiment with peptide 7 was carried out. 
Furthermore, the peptide also binds Thioflavin T when it is in the Soff state, thus in a β-sheet 
conformation. This further confirms that the fibrils formed by the peptide are indeed amyloid-
like fibrils (Figure 82, right). 
The binding of peptide 7 in the Son state to ThT was also examined and revealed that the peptide 
did not exhibit any fluorescence when it was in the Son state, thus in an α-helical conformation 
(Figure 82, right, orange bar). Therefore, we can conclude that a conformational transition from 
β-sheet to soluble α-helical structure of the peptide has occurred and that amyloid fribrils have 
effectively been destabilized and cleared. 
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Figure 82. Left: Absorbance spectra of CR alone (full line), in the presence of peptide 7 in the Soff state 
(dashed line) and preformed a-synuclein fibrils (dotted line). Right: ThT fluorescence of peptide 7 in 25% 
TFE in the Soff state (green), as well as after O to N acyl migration and filtration through a 10 kDa 
membrane filter (orange), ThT control (black). 
Heat induced dissociation/denaturation 
 
To better understand the structural properties of peptide 7, we probed its stability in the Son and 
Soff state towards heat-induced dissociation/denaturation. To this end, the peptide solutions are 
heated gradually and the conformation of the peptide is monitored by CD (Figure 83). Heating of 
peptide 7 in the Soff state (pH 4.5, 25°C, green curve) to 95°C results in a transition from β-sheet 
to a predominantly unordered structure (black curve). Interestingly, upon cooling the sample to 
25°C, the peptide does not return to its original β-sheet structure, but rather forms an α-helical 
structure (orange curve), pointing to the onset of the helix-inducing effect of the Ncap at high 
temperature (due to temperature induced O,N-acyl migration and activation of the Ncap). Most 
notably, once the β-sheet is destabilized at high temperature, the helix-inducing effect of the 
Ncap is strong enough to overcome the intrinsic β-sheet potential of peptide 7, i.e. a Ncap-
induced transition of type random-coil (95°C) to α-helix (25°C) is observed.  
 
Moreover, at pH 7 and in the absence of TFE, peptide 7 (Son state) does not exhibit a clear α-
helical structure but when heated to 95°C and cooled back to 25°C the peptide undergoes a 
transformation similar to the one previously observed at pH 4.6.  
Chapter II  Results & Discussion 
 
 108 
 
Figure 83. Monitoring conformational transition of peptide 7 by CD (c = 5 x 10-5 M): A) in buffer pH 
4.6 and B) in buffer pH 7. 
Conformation of peptide 7 in the Soff state in TFE 
TFE is commonly used as a co-solvent in protein folding studies, this solvent can effectively 
solubilize both peptides and proteins and it is known that, depending upon its concentration, TFE 
can strongly affect the three-dimensional structure of proteins and facilitates helix formation by 
affecting hydrophobic interactions. 
It is noteworthy that in the presence of TFE alone (20-100%), the conformation of peptide 7 is 
not affected and the peptide still forms predominantly β-sheet rich fibrillar aggregates (Figure 
84).  
It confirms that the helix nucleating template is necessary to enable peptide 7 to undergo a 
conformational transition from β-sheet to α-helix. 
 
Figure 84. CD spectrum (A) and negatively stained electron micrograph (B) of peptide 7 dissolved 
directly in 100 % TFE 
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6.4. Conclusion and perspective 
 
Using peptide 7, we were able to investigate the feasibility of disrupting amyloid formation 
through controlled induction of β-sheet to α-helix transformation of the self-assembled peptides 
within the amyloid structure. The experimental data offer new insights into the stability and 
structural properties of amyloid fibrils.  
Our studies support the dynamic structure of amyloid133, 134, 151 and demonstrate that significant 
structural rearrangements can take place within the β-sheet structure of amyloid fibrils. 
Furthermore, these studies demonstrate for the first time that structural changes in polypeptide 
regions140 that are not involved in amyloid formation could have significant impact on the 
stability and structural dynamics of amyloid fibrils.  
Developing tools to disrupt and/or reverse β-sheet based self-assembly have important 
implications for understanding the mechanisms of protein aggregation and clearance in vivo and 
the development of therapeutic strategies aimed at preventing/reversing amyloid formation.  
The ability to control the structure and morphology of the aggregates formed by peptide 7 
suggest that engineering specific switch elements and/or structure templating motifs within 
amyloid forming proteins and peptides could provide the necessary means to correlate structural 
differences between the different amyloid morphologies with toxicity.  
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Chapter III. Experimental part 
1. Instrumentation and general methods 
Reagents and solvents 
Solvents and reagents were purchased from Fluka (Buchs, Switzerland), Sigma-Aldrich Chemie 
GmbH (Steinheim, Germany) or Acros (Geel, Belgium). Amino acids derivatives, resins and 
coupling reagents were obtained by Calbiochem-Novabiochem (Läufelfingen, Switzerland), 
Bachem Fine Chemicals (Bubendorf, Switzerland) or Alexis (Läufelfingen, Switzerland). DMF 
for peptide synthesis was purchased from SdS (Peypin, France) and degassed with nitrogen 
before use. Acetonitrile for analytical and preparative HPLC was obtained from Biosolve BV 
(Valkenswaard, Netherlands). Water used for HPLC was a Milli-Q quality, collected after 
passing through a Millipore Milli-Q purification system (Volketswil, Switzerland). 
Trifluoroacetic acid used for HPLC was purchased from Baker AG (Basel, Switzerland). 
 
Chromatography 
Analytical reversed-phase HPLC spectra were recorded on a Waters system (Waters 
Corporation, Milford, MA, USA) consisting of two Waters 600 pumps, a Waters 600 System 
Controller, a Waters 486 Tunable Absorbance Detector and a printer Waters 746, using columns 
packed with Vydac Nucleosil 218TP54 C18 particles (250 x 4.6 mm), or 208TP54 C8 particles 
(250 x 4.6 mm). Flow rates of 1 mL/min were used and the UV absorbance was monitored at 
214 nm. All gradients were linear in eluent A (0.09% TFA in 90% aqueous acetonitrile) and 
eluent B (0.09% TFA in water). 
 
Preparative HPLC purifications were performed on a Waters Delta Prep 3000 System, with a 
Waters 600E System Controller and a Waters 484 Absorbance Detector, with Vydac Nucleosil 
218TP152050R C18 particles (5 x 25 cm). Flow rates of 80 mL/min were used and the UV 
absorbance was monitored at 214 nm. All gradients were linear in eluent A (0.09% TFA in 90% 
aqueous acetonitrile) and eluent B (0.09% TFA in water). 
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Semi-Preparative HPLC purifications were performed on a Waters Delta Prep 3000 System, with 
a Waters 600E System Controller and a Waters 484 Absorbance Detector, with Vydac Nucleosil 
218TP152050R C18 particles (22mm), or 208TP1022 C8 particles (2.2 x 25cm). Flow rates of 18 
mL/min were used and the UV absorbance was monitored at 214 nm. All gradients were linear in 
eluent A (0.09% TFA in 90% aqueous acetonitrile) and eluent B (0.09% TFA in water). 
For column chromatography, silica gel SiO2 merck 60 (0.040 – 0.063 mm, 230 – 400 Mesh) was 
used. 
 
Mass spectroscopy 
Electrospray ionization (ESI-MS) mass spectra were recorded on a Finnigan MAT SSQ 710 C 
spectrometer equipped with an IBM PS1295XP486 (software Technivent Vector II) in positive 
ionization mode with CH3CN/H2O/CH3COOH 50:50:1 as solvent. 
Whenever mass was higher than 2000 g/mol, mass was performed on a matrix-assisted laser 
desorption/ionization time of flight mass spectrometer MALDI-TOF Axima-CFR Shimadzu. All 
spectra were acquired in the reflectron mode or linear mode using α-cyano matrix. 
 
Circular Dichroism (CD) spectroscopy 
CD spectra were recorded on a JASCO J-810 spectropolarimeter using a bandwidth of 1nm, a 
data pitch of 0.5 nm, step scanning mode, a response of 0.25 sec and an accumulation of 2. 
Spectra were recorded from 195 nm to 250 nm using Time course or Interval scan measurements 
and a 0.1 cm cuvette.  
 
Electron Microscopy (EM) 
5 µL aliquots of switch-peptide solutions were adsorbed for two minutes on a carbon-coated 
200-mesh copper grid and stained with a solution of 2% uranyl acetate for 1min. After removal 
of excess liquid by blotting with filter paper, specimens were examined in a JOEL 1210 electron 
microscope, operated at 100 kV. Digitized photographs were recorded with a slow scan CCD 
camera (Gatan, Model 679). Magnification calibration was performed using catalase crystals. 
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Thioflavin T fluorescence assay (ThT) 
Fibril formation was monitored by a thioflavin T (ThT) (Sigma) fluorescence assay. Readings 
were carried out at a final protein and Th T concentration of 10µM, made up in a final volume of 
100µl of 50mM Glycine-NaOH buffer (pH 8.5).  
Th T fluorescence measurements were recorded on an Analyst Fluorescence instrument (LJL 
Biosystems, Sunnyvale CA, U.S.A) at an excitation and emission wavelength of 450 nm and 485 
nm, respectively. The relative fluorescence at 485 nm was used as a measure of the amount of 
fibrillar aggregates formed in solution. All samples were analysed in triplicates and corrected for 
the fluorescence level of the studied peptide at time 0. Data were plotted using Microcal Origin. 
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2. Solid-Phase Peptide Synthesis 
General 
 
The syntheses were carried out manually in a cylindrical vessel with a fritted disc and a 
removable lid equipped with a mechanical stirrer. Before each synthesis, silylation overnight of 
the glassware with a 25% solution of dichlorodimethylsilane in dry toluene is required to 
improve the surface hydrophobicity and prevents the beads from sticking to the wall of the 
vessel. The resin should be swollen with DCM for at least one hour and DMF degassed for at 
least 2 hours. Standard procedures of solid phase peptide synthesis using the Fmoc/tBu strategy 
were performed using 2-chlorotrityl, Rink amide MBHA, pre-loaded NovasynTGA  or Sieber 
amide resins. 
Coupling reaction 
 
For a standard coupling, 2 eq of Fmoc-Xaa-OH and 2eq of PyBOP were first dissolved in 
degassed DMF and added to the resin, 4 eq of DIPEA were then added to the vessel. Coupling 
reaction time varied from 30 min to 60 min. Some other couplings were performed with HATU, 
and the number of equivalents increased to 4 eq. 
Esterification method 
 
3 eq of Fmoc-Ala-OH, Fmoc-Phe-OH, Fmoc-Val-OH, Fmoc-Gly-OH or Fmoc-Leu-OH and 0.1 
eq of DMAP were dissolved in a mixture of DCM/DMF (4:1) and added to the resin, 3 eq of 
DIC were then added to the vessel. After 2 hours, a cleavage test was performed and the extent 
of esterification controlled by HPLC. If completion was not achieved, a second or third 
esterification was performed. 
Fmoc deprotection 
 
The Fmoc group was usually removed by treating the resin with a solution of 20% piperidine in 
DMF (2x10min). In switch-peptide 21 synthesis, a mixture of 2% DBU and 5% piperidine in 
DMF (2x5min) was sometimes used to avoid incomplete deprotection. When Rink amide 
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MBHA resin is used, the first Fmoc-group was removed with a solution of 20% piperidine in 
DMF for 5x2min and 1x10min. 
Colorimetric tests 
 
Kaiser test 
 
Solution 1: 1 g ninhydrin in 20 mL of ethanol. 
Solution 2: 80 g phenol in 20 mL of ethanol. 
Solution 3: 2 mL 0.001 M aqueous KCN in 98 mL of pyridine.  
 
A few resin beads were placed in a small test tube and 2 drops of each solution were added. The 
tube was then heated to 100°C for 3 min. A positive test is indicated by the presence of blue 
resin beads. 
Chloranil test 
 
Solution 1: 2% acetaldehyde in DMF. 
Solution 2: 2% chloranil in DMF. 
 
A few resin beads were placed in a small test tube and 2 drops of each solution were added. The 
mixture was then left at room temperature for 5 min and the beads inspected. A positive test is 
indicated by the presence of blue resin beads. 
Acetylation 
 
20 eq of acetic anhydride and 10 eq of pyridine in DMF were added to the resin and the reaction 
was carried out for 30 min. 
Cleavage of peptide from the resin 
 
The resin was treated with a solution of TFA/TIS/H2O 95:2.5:2.5 twice for 1 hour or, in the case 
of Sieber amide resin, with 1% TFA in DCM for 1 hour. 
After washing with TFA and MeOH, the solvents were evaporated under high vacuum and the 
peptides were precipitated with cold diethyl ether. After centrifugation, the peptides were 
purified by preparative or semi-preparative HPLC.  
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Sieber amide resin was washed with DCM alone. Toluene was added to the solution in order to 
get rid of TFA via an azeotrope. The peptide was then precipitated with cold ether, centrifuged, 
and purified by preparative HPLC. 
Small cleavage assays 
 
Small cleavage assays were performed at different stages during solid phase synthesis in order to 
check the correct evolution of the synthesis. For this purpose, a few beads of resin were treated 
with a solution of TFA/TIS/H2O 95:2.5:2.5 for 30 min. After filtration through a Millex Syringe 
Driven Filter Unit 0.22 µm and precipitation in cold diethyl ether, the samples were analyzed by 
mass spectrometry and HPLC.  
3. Synthesis 
3.1. Building block synthesis 
Fmoc-Leu-(Boc)Ser-OBzl1 (1) 
HN
O
O
H
N
O
O
O
O
O
O
 1 
Fmoc-Leu-OH (1 g, 2.83 mmol) and Boc-Ser-OH (0.84 g, 2.83 mmol) were dissolved in 25 mL 
DCM, DIC and DMAP were added to the solution. After stirring over night, the mixture was 
washed successively with 5% citric acid, 10% NaOH and brine and dried over CaCl2. After 
removal of the solvent, the colorless oil was purified by column chromatography 
                                                
1 We follow the proposed nomenclature for depsipeptides. See: S. V. Filip, F. Cavelier, J. Pept. 
Sci. 2004, 10, 115-118.  
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(Hexane/EtOAc 3:1) to give 1 as a white powder (1.55 g, 86%, C36H42N2O8, MW = 630.73 
g/mol). 
ESI MS: (m/z) 531.33 [M-Boc + H]+, 631.32 [M + H]+. 
HPLC: Rt = 30 (C18 0 to 100 A in 30 min). 
1H-NMR: (400MHz, CDCl3), d (ppm) 0.94 (dd, 6H, 2CH3-Leu), 1.28 (t, 2H, CH2-Leu), 1.44 (s, 
9H, (CH3)3-Boc), 1.58 (m, 1H, CH-Leu).  
 
Fmoc-Leu-(Boc)Ser-OH (2) 
HN
O
O
H
N
OH
O
O
O
O
O
 2 
To a solution of Fmoc-Leu-(Boc)Ser-OBzl (500 mg, 0.79 mmol) in 30 mL MeOH was added 50 
mg Pd on activated charcoal. A stream of H2 mixed with N2 was continuously bubbled through 
the mixture with stirring and after 2h at room temperature, the mixture was passed through celite, 
washed with MeOH, and evaporated under vacuum to give a white powder that was purified by 
preparative-HPLC and yielded 2 as a white powder (340 mg, 80%, C29H36N2O8), MW = 540.25 
g/mol). 
ESI MS: (m/z) 441.35 [M-Boc + H]+, 541.30 [M + H]+. 
HPLC: Rt = 13.9 (C18 50 to 85 A in 20 min). 
 
NVOC-Ser-OBzl (3) 
OH
H
N
O
O
O
O
NO2
O
O
     3 
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H-Ser-OBzl (1.18 g, 5.08 mmol) and DIEA (1.66 mL, 10.16 mmol, 2 eq) were dissolved in 20 
mL DCM. NVocCl (1.2 g, 5.08 mmol) were added to the solution. After stirring 30 min, the 
mixture was diluted with 60 mL DCM, washed twice with 1N HCl, dried over MgSO4, filtered 
and dried under vacuun to give an orange solid that was pure by HPLC (1.78 g, 94%, 
C20H22N2O9, MW = 434.40 g/mol). 
ESI-MS: (m/z) 435.17 [M + H]+. 
HPLC: Rt = 20.9 min (C18, 0 to 100% A in 30 min). 
 
Fmoc-Gly-(NVOC)Ser-OBzl (4) 
HN
O
O
H
N
O
O
O
O
O
O
NO2
O
O
4 
Fmoc-Gly-OH (1.16 g, 3.9 mmol), NVOC-Ser-OBzl (1.7 g, 3.9 mmol) and DMAP (47 mg, 0.39 
mmol, 0.1 eq) were suspended in 15 mL DCM and EDCI (900 mg, 4.6 eq) was added and all 
contents fully dissolved. After stirring 1.5h, the mixture was chilled and filtered to remove the 
urea byproduct then diluted with DCM and washed successively with 5% citric acid, 5% 
NaHCO3 and Brine. Drying over MgSO4 and removal of solvent yielded 4 as an orange powder 
(2.7 g, quantitative, C37H35N3O12, MW = 713.22 g/mol). 
ESI-MS: (m/z) 714.34 [M + H]+, 731.32 [M + H2O]+. 
HPLC: Rt = 28 (C18 0 to 100% A in 30 min) 
 
Fmoc-Gly-(NVOC)Ser-OH (5) 
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HN
O
O
H
N
OH
O
O
O
O
O
NO2
O
O
    5 
Fmoc-Gly-(NVOC)Ser-OBzl (2 g, 2.8 mmol) was dissolved in 20 mL THF. N2 atmosphere was 
applied for 15 min and then, 0.2 g Pd on activated charcoal were added to the solution. A stream 
of H2 was continuously bubbled through the mixture with stirring and after 24h at room 
temperature, the mixture wash flushed with N2 for 5 min, passed through celite and evaporated 
under vacuum to give 5 as an orange powder that was pure by HPLC (1.56 g, 90%, C30H29N3O12, 
MW = 623.56 g/mol). 
ESI-MS: (m/z) 624.52 [M + H]+, 641.56 [M + H2O]+. 
HPLC: Rt = 22.8 (C18 0 to 100% A in 30 min) 
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3.2. Synthesis of switch-peptides of amyloid β  fibril disrupting potential 
Synthesis of the dipeptides Ac-Leu-Cys(ΨMe,Mepro)-OH and Ac-Leu-Cys(ΨH,Hpro)-OH 
 Pseudo-proline H-Cys(ΨMe, Mepro)-OH (10) 
L-cysteine hydrochloride (2 g, 11.4 mmol, 1eq) was suspended in 160 mL of acetone. After 
addition of 36 mL (318.8 mmol, 14eq) of dimethoxypropane, the suspension was stirred and 
heated to reflux for 2h. The reaction mixture was cooled down, filtered to yield 10 as a white 
powder (1.85 g, quantitative). 
1H NMR (400 MHz, d6-DMSO): δ (ppm) 1.74 (s, 6H, CH3); 3.40 (dd, 1H, Hb); 3.53 (dd, 1H, 
Hb’); 4.90 (t, 1H, Ha) 
 
 Pseudo-proline H-Cys(ΨH, Hpro)-OH (11) 
L-cysteine hydrochloride (3.5 g, 20 mmol, 1eq) and 4 mL of 40% formaldehyde were left 
overnight at room temperature in 10 mL water. Addition of 10 mL of absolute EtOH and 6 mL 
of pyridine gave crystals which were collected, washed with EtOH and Et2O, and air-dried to 
give 1.9 g (72%) of 11 as a white powder. 
1H NMR (400 MHz, d6-DMSO): δ (ppm) 3.22 (dd, 1H, Hb1); 3.29 (dd, 1H, Hb2); 3.53 (dd, 1H, 
Hb’); 4.25 (t, 1H, Ha); 4.6 (s, 2H, CH2) 
 
Activated Ac-Leu-F (12) 
To a suspension of Ac-Leu-OH (840 g, 4.85 mmol) in 20 mL DCM, was added droppwise under 
nitrogen,  720 µL (5.81 mmol, 1.2 eq) of DAST. The reaction mixture was stirred for 15 min at 
room temperature. The solution was then extracted rapidly with iced water and the organic phase 
dried over MgSO4. The resulting Ac-Leu-F was immediately used for the next coupling reaction. 
 
Dipeptide Ac-Leu-Cys(ΨMe,Mepro)-OH (13) 
To the reactive Ac-Leu-F (4.85 mmol, 1eq) in DCM was added 790 mg of compound 10 (4.85 
mmol) and 1.6 mL (9.7 mmol, 2 eq) of DIEA. The reaction was stirred at room temperature for 
one hour and the solvent was evaporated. The crude was then purified by preparative HPLC 
(C18, 0 to 100% A in 30 min) to yield 13 as a white powder (554 mg, 36%). 
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Dipeptide Ac-Leu-Cys(ΨH,Hpro)-OH (14) 
To the reactive Ac-Leu-F (4.85 mmol, 1eq) in DCM was added 645 mg of compound 11 (4.85 
mmol) and 1.6 mL (9.7 mmol, 2 eq) of DIEA. The reaction was stirred at room temperature for 
one hour and the solvent was evaporated. The crude was then purified by preparative HPLC 
(C18, 10 to 30% A in 30 min) to yield 14 as a white powder (556 mg, 40%).   
 
Synthesis of β-breaker switch-peptides 
All β-breakers were synthesized on a Sieber amide MBHA resin (loading 0.71 mmol/g). Each 
coupling was performed with 2 eq of PyBop and 4 eq of DIEA, except for the last coupling 
where PyBop was replaced by HATU. After each coupling, the resin washed with DMF and 
DCM and Kaiser test was performed. Fmoc group was removed with a solution of 20% 
piperidine in DMF. The switch element was constructed by first coupling Boc-Ser-OH without 
side-chain protection. Fmoc-Ala-OH was then coupled via an ester bond to the free side-chain of 
Ser with DIC (46 µL; 3 eq) and DMAP (6 mg; 0.5 eq). 
After coupling of the dipeptide building block containing pseudoproline, the peptide was cleaved 
from the resin with a solution of 1% TFA in DCM (5*10 min). After each cleavage cycle, the 
filtrate is collected in a flask containing 50 mL of toluene. After the last cycle, the solvent is 
evaporated and the peptide is precipitated with cold diethylether, centrifuged and washed 3 times 
with cold ether. The peptide was then redissolved in a mixture of water/acetonitrile and 
lyophilized.  
 
Synthesis of Ac-Leu-Cys(ΨMe,Mepro)-Ala-(H+)Ser-Phe-Phe-Asp-NH2 (15) 
 
Sieber amide resin: 0.10 mmol; 150 mg (loading 0.71 mmol/g) 
Amino Acids MW Quantity (mg) 
No.of equivalents 
Coupling 
time (min) 
Remarks 
Fmoc-Asp(t-Bu)-OH 411.5 83/ 2 eq  60  Kaiser (-) 
Fmoc-Phe-OH 387 78/ 2 eq 60  Kaiser (-) 
Fmoc-Phe-OH 387 78/ 2 eq 60  Kaiser (-) 
Boc-Ser-OH 474 41/ 2 eq  60  Kaiser (-) 
Fmoc-Ala-OH 311 94/ 3 eq 2*120  esterification 
Ac-Leu-Cys(ΨMe,Mepro)-OH 316 50/ 2 eq 160   
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Cleavage of protecting groups 
The crude peptide was suspended in a solution of TFA/DCM/TIS/H2O (50/40/5/5) 50 mL for 
1h30. 50 mL of toluene was added to the reaction to facilitate the removal of TFA and thus 
prevent pseudoproline opening. After evaporation, few drops of DCM were added to the flask 
and the peptide was precipitated with diethylether. Purification by preparative HPLC (0 to 100% 
A in 30 min) yielded 15 as a white powder (13 mg; 15%). 
ESI-MS: (m/z) 883.20 [M + H]+. 
HPLC: Rt = 20.5 (C18 0 to 100% A in 30 min). 
 
Synthesis of Ac-Leu-Cys(ΨH,Hpro)-Ala-(H+)Ser-Phe-Phe-Asp-NH2 (16) 
 
Sieber amide resin: 0.13 mmol; 240 mg (loading 0.55 mmol/g) 
Amino Acids MW Quantity (mg) 
No.of equivalents 
Coupling 
time (min) 
Remarks 
Fmoc-Asp(t-Bu)-OH 411.5 107/ 2 eq  60  Kaiser (-) 
Fmoc-Phe-OH 387 100/ 2 eq 60  Kaiser (-) 
Fmoc-Phe-OH 387 100/ 2 eq 60  Kaiser (-) 
Boc-Ser-OH 474 53/ 2 eq  60  Kaiser (-) 
Fmoc-Ala-OH 311 128/ 3 eq 2*120  esterification 
Ac-Leu-Cys(ΨMe,Mepro)-OH 288 74/ 2 eq 160   
 
Cleavage of protecting groups 
The crude peptide was suspended in a solution of TFA/DCM/TIS/H2O (60/30/5/5) 50 mL for 2h. 
50 mL of toluene was added to the reaction to facilitate the removal of TFA and thus prevent 
pseudoproline opening. After evaporation, few drops of DCM were added to the flask and the 
peptide was precipitated with diethylether. Purification by preparative HPLC (0 to 100% A in 30 
min) yielded 16 as a white powder. 
ESI-MS: (m/z) 855.36 [M + H]+. 
HPLC: Rt = 15.7 (C18 0 to 100% A in 30 min). 
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Synthesis of Ac-Leu-Cys(ΨMe,Mepro)-Ala-(H+)Ser-(NMe)Phe-Phe-Asp-NH2 (17) 
 
Sieber amide resin: 0.23 mmol; 440 mg (loading 0.55 mmol/g) 
Amino Acids MW Quantity (mg) 
No.of equivalents 
Coupling 
time (min) 
Remarks 
Fmoc-Asp(t-Bu)-OH 411.5 189/ 2 eq  60  Kaiser (-) 
Fmoc-Phe-OH 387 178/ 2 eq 60  Kaiser (-) 
Fmoc-(NMe)Phe-OH 387 185/ 2 eq 60  HATU/ Kaiser (-) 
Boc-Ser-OH 474 94/ 2 eq  60  HATU/ Kaiser (-) 
Fmoc-Ala-OH 311 230/ 3 eq 2*120  esterification 
Ac-Leu-Cys(ΨMe,Mepro)-OH 316 145/ 2 eq 120  
 
Cleavage of protecting groups 
The crude peptide was suspended in a solution of TFA/DCM/TIS/H2O (50/40/5/5) 50 mL for 
1h30. 50 mL of toluene was added to the reaction to facilitate the removal of TFA and thus 
prevent pseudoproline opening. After evaporation, few drops of DCM were added to the flask 
and the peptide was precipitated with diethylether. Purification by preparative HPLC (0 to 100% 
A in 30 min) yielded 17 as a white powder. 
ESI-MS: (m/z) 897.80 [M + H]+. 
HPLC: Rt = 18.2 (C18 0 to 100% A in 30 min). 
 
 
Synthesis of Ac-Leu-Cys(ΨH,Hpro)-Ala-(H+)Ser-(NMe)Phe-Phe-Asp-NH2 (18) 
 
Sieber amide resin: 0.14 mmol; 255 mg (loading 0.55 mmol/g) 
Amino Acids MW Quantity (mg) 
No.of equivalents 
Coupling 
time (min) 
Remarks 
Fmoc-Asp(t-Bu)-OH 411.5 115/ 2 eq  60  Kaiser (-) 
Fmoc-Phe-OH 387 108/ 2 eq 60  Kaiser (-) 
Fmoc-(NMe)Phe-OH 387 112/ 2 eq 60  Kaiser (-)/ HATU 
Boc-Ser-OH 474 58/ 2 eq  60  Kaiser (-)/ HATU 
Fmoc-Ala-OH 311 138/ 3 eq 2*120  esterification 
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Ac-Leu-Cys(ΨH,Hpro)-OH 288 80/ 2 eq 120  
 
Cleavage of protecting groups 
The crude peptide was suspended in a solution of TFA/DCM/TIS/H2O (60/30/5/5) 50 mL for 2h. 
50 mL of toluene was added to the reaction to facilitate the removal of TFA and thus prevent 
pseudoproline opening. After evaporation, few drops of DCM were added to the flask and the 
peptide was precipitated with diethylether. Purification by preparative HPLC (0 to 100% A in 30 
min) yielded 18 as a white powder (20 mg; 16%). 
ESI-MS: (m/z) 869.37 [M + H]+. 
HPLC: Rt = 16.5 (C18 0 to 100% A in 30 min). 
 
Synthesis of Ac-Leu-Cys(ΨMe,Mepro)-Ala-(Arg-Pro)Ser-(NMe)Phe-Phe-Asp-NH2 (19) 
 
Sieber amide resin: 0.23 mmol; 440 mg (loading 0.55 mmol/g) 
Amino Acids MW Quantity (mg) 
No.of equivalents 
Coupling 
time (min) 
Remarks 
Fmoc-Asp(t-Bu)-OH 411 189/ 2 eq  60  Kaiser (-) 
Fmoc-Phe-OH 387 178/ 2 eq 60  Kaiser (-) 
Fmoc-(NMe)Phe-OH 387 185/ 2 eq 60  Kaiser (-)/ 
HATU 
Boc-Ser-OH 474 94/ 2 eq  60  Kaiser (-)/ 
HATU 
Fmoc-Pro-OH 337 155/ 2 eq 60  
Boc-Arg(Boc)2-OH 474 218/ 2 eq 60  
Fmoc-Ala-OH 311 230/ 3 eq 2*120  esterification 
Ac-Leu-Cys(ΨMe,Mepro)-OH 316 145/ 2 eq 120  
 
Cleavage of protecting groups 
The crude peptide was suspended in a solution of TFA/DCM/TIS/H2O (50/40/5/5) 50 mL for 
1h30. 50 mL of toluene was added to the reaction to facilitate the removal of TFA and thus 
prevent pseudoproline opening. After evaporation, few drops of DCM were added to the flask 
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and the peptide was precipitated with diethylether. Purification by preparative HPLC (0 to 100% 
A in 30 min) yielded 19 as a white powder (42 mg; 18%). 
ESI-MS: (m/z) 1150 [M + H]+, 576 [M + 2H]2+ 
HPLC: Rt = 17 (C18 0 to 100% A in 30 min). 
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3.3. Switch-Peptide 7 
Ac-Lys-Ala-Arg-Ala-Asp-Ala-O
H-Ser-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-NH2
       7 
 
The peptide was prepared by stepwise solid-phase synthesis (SPPS) using Fmoc/tBu protection 
and Rink amide resin that was preswollen with dichloromethane (DCM) for 30 min. Standard 
amide couplings involved dissolving 2.5 equivalents Fmoc-amino acid with equimolar amounts 
of PyBOP and collidine in DMF and stirring five minutes. The preactivated mixture was added 
to the resin swollen in DMF, together with an equimolar amount of DIEA. Coupling reaction 
times were in the range of 30-90 min and completeness of the couplings was verified by Kaiser 
test with repeat couplings performed if needed. To effect Fmoc cleavage, the peptide-resin was 
treated with a 20% solution of piperidine in DMF (2 x 10 min) and then washed with DMF (3X) 
and DCM (3x). 
Resin cleavage: The peptide-resin was treated with a solution of TFA/TIS/H2O/DODT (95:2:2:1) 
2 x 1 h. Following evaporation of the bulk of the TFA with a stream of dry nitrogen, the peptide 
was precipitated by the addition of cold ether, collected by filtration, and washed repeatedly with 
cold ether. 
 
Fmoc-Ala-(Boc)Ser-OBzl: Fmoc-Ala-OH (200 mg, 0.64 mmol), Boc-Ser-OBzl (190 mg, 0.64 
mmol), and DMAP (8.0 mg, 0.064 mmol) were combined in 5 mL DCM with a few drops of 
DMF added to fully dissolve the contents and DIC (0.10 mL, 0.64 mmol) was added. After 
stirring 1 h, the mixture was chilled and filtered to remove the urea byproduct then diluted with 
30 mL DCM and washed successively with 5% citric acid, 5% NaHCO3, and brine. Drying with 
MgSO4 and removal of solvent yielded a colorless oil that was purified by column 
chromatography (EtOAc/hexane 4:6) to yield 7 as a white powder (260 mg, 70%, C33H36N2O8, 
m/z calculated: 588.65).  
ESI-MS: (m/z) 489.38 [M – Boc + H]+, 589.38 [M + H]+. 
HPLC: Rt = 29.1 (C18, 5 to 95% A in 30 min). 
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Fmoc-Ala-(Boc)Ser-OH: To a solution of Fmoc-Ala-(Boc)Ser-OBzl (200 mg, 0.34 mmol) in 10 
mL MeOH, 10 mg Pd on activated charcoal was added. A stream of H2 mixed with N2 was 
continuously bubbled through the mixture with stirring and after 1 h at room temperature, the 
mixture was passed through celite and evaporated under vacuum to yield a white powder that 
was pure by HPLC (168 mg, quant., C26H30N2O8, m/z calculated: 498.53).  
ESI-MS: (m/z) 398.84 [M – Boc]. 
HPLC: Rt = 24.0 (C18, 5 to 95% A in 30 min). 
 
Fmoc-[(cyclo-1-5)-Lys-Ala-Arg(Pbf)-Ala-Asp]-OH: Synthesis of peptide I started by the 
preparation of the N-cap protected lactam-bridged pentapeptide that could be used as building 
block in SPPS. This was accomplished using the method developed by Shepherd et al [15b]. The 
solid phase synthesis of a lactam-bridged peptide requires an orthogonal protection of the side 
chains to be cyclized. In Fmoc/tBu SPPS, this need is met by the use of Alloc/Allyl, which is 
removed by Pd0 catalyzed reduction. The peptide is constructed and cyclized on a highly acid 
labile support. Cleavage can then be performed under mild acidic conditions to give a peptide 
fragment that is fully protected and contains a free acid at the C-terminus. 
 
Peptide 7: The fibril-forming peptide HQKLVFFAEDVG was assembled on Rink amide resin 
(0.60 mmol/g, 0.30 g, 0.18 mmol), using automated synthesis, a glycine residue was included at 
the C-terminal end to serve as a spacer. The switch-element was introduced by manually 
coupling the depsidipeptide Fmoc-Ala-(Boc)Ser-OH. After Fmoc removal, the N-capping 
template Fmoc-(cyclo-1-5)-KARAD-OH was coupled manually to give Fmoc-[(cyclo-1-5)-
KARAD]A-S1-HQKLVFFAEDVG-NH2 where S1 = (+H)Ser. As both the N-cap and the switch-
element were introduced as building blocks, all couplings were PyBOP mediated amide 
couplings, and the synthesis was straightforward. Following Fmoc deprotection, the peptide was 
treated with an excess of Ac2O and pyridine in DMF for 1 h. Cleavage from the resin and 
purification by semi-preparative HPLC (C8, 10 to 60% A, 30 min) afforded the desired peptide I 
as a white powder with > 95% purity (12 mg, C95H146N28O27, m/z calculated: 2112.35).  
ESI-MS: (m/z) 1056.86 [(M + 2H)/2]+, 704.81 [(M + 3H)/3]+, 529.31 [(M + 4H)/4]+.  
HPLC: Rt = 5.93 (C18, 0 to 30% A in 10 min). 
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Amino Acids Coupling 
No. 
Quantity (mg) 
No.of equivalents 
Coupling 
time (min) 
Remarks 
Fmoc-Gly-OH 1 (134/ 2.5 eq)  2 x 30   
Fmoc-Val-OH 2 (153/ 2.5 eq) 2 x 30   
Fmoc-Asp(OtBu)-OH 3 (185/ 2.5 eq) 2 x 30  
Fmoc-Glu(OtBu)-OH 4 (200/ 2.5 eq)  2 x 30  
Fmoc-Ala-OH.H2O 5 (148/ 2.5 eq) 2 x 30  
Fmoc-Phe-OH 6 (174/ 2.5 eq) 2 x 30  
Fmoc-Phe-OH 7 (174/ 2.5 eq) 2 x 30   
Fmoc-Val-OH 8 (153/ 2.5 eq) 2 x 30  
Fmoc-Leu-OH 9 (159/ 2.5 eq) 2 x 30  
Fmoc-Lys(Boc)-OH 10 (211/ 2.5 eq) 2 x 30  
Fmoc-Gln(Trt)-OH 11 (275/ 2.5 eq) 2 x 30  
Fmoc-His(Trt)-OH 12 (279/ 2.5 eq) 2 x 30 Kaiser (-) 
Fmoc-Ala-(Boc)Ser-OH 13 (302/ 3.0 eq) 90 manual coupling 
Kaiser (-) 
Fmoc-[(cyclo-1-5)-Lys-
Ala- 
Arg(Pbf)-Ala-Asp]-OH 
14 (260/ 1.5 eq) 180 manual coupling 
Kaiser (-) 
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3.4. Host-Guest Switch-Peptide 8 
H-Arg-Pro-Ser-Glu-Asp-Val24-Ser-Leu-Gly-NH2
Ac-Ser-Leu-Ser-Leu-14His-Gln-Lys-Leu-Val-Phe-Phe-O
         8 
 
The amyloid derived host guest switch-peptide 8 was assembled on 500 mg of Rink amide 
MBHA resin (loading 0.64 mmol/g) by Dr. Sonia Dos Santos within her PhD Thesis. 
Each coupling was performed with 2 eq of PyBop and 4 eq of DIEA. After each coupling, the 
resin  was washed with DMF and DCM and a Kaiser test was performed after each step. Fmoc 
group was removed with a solution of 20% piperidine in DMF. The switch element was 
constructed by first coupling Fmoc-Ser-OH without side protection followed by Fmoc-Pro-OH 
and Boc-Arg(di-Boc)-OH which were coupled normally. Fmoc-Phe-OH was then coupled via an 
ester bond to the free side chain of the Ser21 with DIC (3eq) and DMAP (0.5eq).  Colorimetric 
tests were negative all along the synthesis and cleavage tests assays indicated the correct 
evolution of the synthesis. 
After deprotection of the last Fmoc group and acetylation of the N-terminus, the peptide was 
cleaved from the resin with a solution of TFA/TIS/H20 (95/2.5/2.5) for 2 x 1h and thereafter, 
precipitated in cold diethylether. The crude peptide was purified by preparative HPLC (C18, 0 to 
60% A in 30 min) to give in a white powder (220 mg, 30%). 
HPLC: Rt = 16.4 (C18, 0 to 100% A in 30 min) 
MALDI-TOF: m/z = 2300 [M+H]+ 
 
Amino Acids Quantity (mg), eq 
Coupling 
time (min) 
Test 
Fmoc-Gly-OH 191/ 2eq 60 Kaiser (-) 
Fmoc-Leu-OH 226/ 2eq 60 Kaiser (-) 
Fmoc-Ser(tBu)-OH 245/ 2eq 60 Kaiser (-) 
Fmoc-Leu-OH 226/ 2eq 60 Kaiser (-) 
Fmoc-Ser(OH)-OH 210/ 2eq 30 Kaiser (-) 
Fmoc-Val-OH 217/ 2eq 60 Kaiser (-) 
Fmoc-Asp(tBu)-OH 264/ 2eq 60 Kaiser (-) 
Fmoc-Glu(tBu)-
OH.H2O 
284/ 2eq 60 Kaiser (-) 
Fmoc-Ser(OH)-OH 210/ 2eq 30 Kaiser (-) 
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Fmoc-Pro-OH 228/ 2eq 30 Kaiser (-) 
Boc-Arg(di-Boc)-OH 304/ 2eq 30 
Cleavage 
HPLC (C18, 0 → 
100%A): Rt = 12.2 
min 
ESI-MS : m/z = 958 
[M+H]+, 
480 [M+2H]2+ 
Fmoc-Phe-OH 372/ 3eq 2x120 
Cleavage 
HPLC (C18, 0 → 
100%A): Rt = 20.9 
min 
ESI-MS : m/z = 1327 
[M+H]+, 
664 [M+2H]2+ 
Fmoc-Phe-OH 248/ 2eq 60 Kaiser (-) 
Fmoc-Val-OH 217/ 2eq 60 Kaiser (-) 
Fmoc-Leu-OH 226/ 2eq 60 Kaiser (-) 
Fmoc-Lys(Boc)-OH 300/ 2eq 60 Kaiser (-) 
Fmoc-Gln(Trt)-OH 391/ 2eq 60 Kaiser (-) 
Fmoc-His(Trt)-OH 397/ 2eq 60 Kaiser (-) 
Fmoc-Leu-OH 226/ 2eq 60 Kaiser (-) 
Fmoc-Ser(tBu)-OH 245/ 2eq 60 Kaiser (-) 
Fmoc-Leu-OH 226/ 2eq 60 Kaiser (-) 
Fmoc-Ser(tBu)-OH 245/ 2eq 60 Kaiser (-) 
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3.5. Host-Guest Switch-Peptide 9 
Ac-Ser-Leu-O
H-Ser-Leu-14His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val24-O
H-Ser-Leu-Gly-NH2
      9 
The amyloid derived host guest switch-peptide 9 was assembled on 1 g of Rink amide MBHA 
resin (loading 0.66 mmol/g). 
Each coupling was performed with 2 eq of PyBop and 4 eq of DIEA. After each coupling, the 
resin was washed with NMP and DCM and a Kaiser test was performed after each step. The four 
first Fmoc groups were removed with a solution of 2% DBU/ 5% piperidine in NMP and 
thereafter with  20 % piperidine in DMF. Switch elements were constructed by first coupling 
Boc-Ser-OH without side chain protection. The next amino acid was then coupled via an ester 
bond to the free side chain of the Ser with DIC 3eq and DMAP 0.5 eq. Colorimetric tests were 
negative all along the synthesis and cleavage tests assays indicated the correct evolution of the 
synthesis. 
After deprotection of the last Fmoc group and acetylation of the N-terminus, the peptide was 
cleaved from the resin with a solution of TFA/TIS/H20 (95/2.5/2.5) for 2 x 1h and thereafter, 
precipitated in cold diethylether. The crude peptide was purified by preparative HPLC (C18, 30 to 
50% A in 30 min) to give 9 as a white powder (500 mg, 36%). 
HPLC: Rt = 16.7 (C18, 0 to 100% A in 30 min) 
ESI-MS: (m/z) 1016.84 [(M + 2H)/2]+, 678.30 [(M + 3H)/3]+, 508.78 [(M + 4H)/4]+. 
 
Amino Acids Quantity (mg), eq 
Coupling 
time (min) 
Test 
Fmoc-Gly-OH 500/ 2.5eq 30 x 2 Kaiser (-) 
Fmoc-Leu-OH 580/ 2.5eq 30 x 2  Kaiser (-) 
Boc-Ser-OH 339/ 2.5eq 30 x 2 Kaiser (-) 
Fmoc-Val-OH 672/ 3eq 120 x 2 Kaiser (-) 
Fmoc-Asp(tBu)-OH 678/ 2.5eq 30 x 2 Kaiser (-) 
Fmoc-Glu(tBu)-
OH.H2O 
732/ 2.5eq 30 x 2 Kaiser (-) 
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Fmoc-Ala-OH 528/ 2.5eq 30 x 2 Kaiser (-) 
Fmoc-Phe-OH 640/ 2.5eq 30 x 2 Kaiser (-) 
Fmoc-Phe-OH 640/ 2.5eq 30 x 2 Kaiser (-) 
Fmoc-Val-OH 560/ 2.5eq 30 x 2 Kaiser (-) 
Fmoc-Leu-OH 580/ 2.5eq 30 x 2 Kaiser (-) 
Fmoc-Lys(Boc)-OH 773/ 2.5eq 30 x 2 Kaiser (-) 
Fmoc-Gln(Trt)-OH 1000/ 2.5eq 30 x 2 Kaiser (-) 
Fmoc-His(Trt)-OH 1020/ 2.5eq 30 x 2 Kaiser (-) 
Fmoc-Leu-OH 580/ 2.5eq 30 x 2 Kaiser (-) 
Boc-Ser-OH 207/ 2eq 30 x 2 Kaiser (-) 
Fmoc-Leu-OH 690/ 3eq 120 x 2 Kaiser (-) 
Fmoc-Ser(tBu)-OH 630/ 2.5eq 30 x 2 Kaiser (-) 
 
 
Chapter III  Experimental part 
 
 133 
3.6. Synthesis of Amyloid-β  (1-42) derived switch-peptide 22 
H-A!(1-24)-Gly-O
NVOC-Ser26-A!(27-35)-Val-O
H-Orn-Pro-Ser37-A!(38-42)-OH
22 
The synthesis was performed on 1 g of a pre-loaded Fmoc-Ala-NovaSyn TGA resin (loading 
0.20 mmol/g).  
The first Fmoc protecting group was removed with a solution of 20% piperidine in DMF (2x10 
min) and the amino acids Fmoc-Ile-OH and Fmoc-Val-OH was coupled with 2 eq of PyBOP.  
The Fmoc group was then removed with a solution of 2% DBU 5% piperidine in DMF.  
HATU was used as coupling reagent all along the synthesis (2eq or 4 eq). 
Switch element S2 at Ser37 was constructed by first coupling Fmoc-Ser-OH without side chain 
protection followed by normal coupling of Fmoc-Pro-OH and Boc-Orn(Boc)-OH. Fmoc-Val-OH 
was then coupled via an ester bond to the free side chain of the serine with DIC 3eq and DMAP 
0.5 eq. 
Switch element S1 at Ser26 was introduced by coupling the depsidipeptide Fmoc-Gly-
(NVOC)Ser-OH as a building block. 
Cleavage test assays were performed during the synthesis and analyzed by HPLC, ESI-MS or 
MALDI-TOF to check the correct evolution of the synthesis. 
 
Residue Quantity (mg) 
Coupling 
conditions Cleavage test remarks 
41 Fmoc-Ile-OH 141 PyBOP, 2eq, 60min 
- 20% piperidine 
40 Fmoc-Val-OH 135 PyBOP, 2eq, 60min 
-  
39 Fmoc-Val-OH 137 HATU, 2eq, 60min 
-  
38 Fmoc-Gly-OH 119 HATU, 2eq, 60min 
-  
37 Fmoc-Ser(OH)-OH 130 PyBOP, 2eq, 60min 
-  
 Fmoc-Pro-OH.H2O 142 PyBOP, 2eq,   
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60min 
Boc-Orn(Boc)-OH 133 PyBOP, 2eq, 60min 
Rt = 13.1 min 
756 [M+H]+ 
- 
36 Fmoc-Val-OH 
203 CDI, 3eq, 
2x120min 
Rt = 21.4 min 
1077 [M+H]+ 
539 [M+2H]2+ 
 
35 Fmoc-Met-OH 149 HATU, 2eq, 60min 
-  
34 Fmoc-Leu-OH 
141 HATU, 2eq, 
60min 
Rt = 22.3 min 
1369 [M+H]+ 
683 [M+2H]2+ 
 
33 Fmoc-Gly-OH 119 HATU, 2eq, 60min 
-  
32 Fmoc-Ile-OH 141 HATU, 2eq, 60min 
-  
31 Fmoc-Ile-OH 141 HATU, 2eq, 60min 
-  
30 Fmoc-Ala-OH.H2O 
124 HATU, 2eq, 
60min 
-  
29 Fmoc-Gly-OH 119 HATU, 2eq, 60min 
-  
28 Fmoc-Lys(Boc)-OH 187 HATU, 2eq, 60min 
-  
27 Fmoc-Asn(Trt)-OH 
239 HATU, 2eq, 
60min 
Rt = 20.2 min 
988 [M+2H]2+ 
659 [M+3H]3+ 
 
25-26 Fmoc-Gly-    
(NVoc)Ser-OH 
374 HATU, 3eq, 
90min 
Rt = 16.9 min 
1180 [M+2H]2+ 
787 [M+3H]3+ 
- 
     
24 Fmoc-Val-OH 137 HATU, 2eq, 60min 
-  
23 Fmoc-Asp(tBu)-OH 164 HATU, 4eq, 60min 
Rt = 19.9 min 
 
 
22 Fmoc-Glu(tBu)-OH 170 HATU, 4eq, 60min 
-  
21 Fmoc-Ala-OH.H2O 
125 HATU, 4eq, 
60min 
-  
20 Fmoc-Phe-OH 
155 HATU, 4eq, 
60min 
 MS after Fmoc 
removal  
1349 [M+2H]2+ 
900 [M+3H]3+ 
675 [M+4H]4+ 
19 Fmoc-Phe-OH 155 HATU, 4eq, 60min 
-  
18 Fmoc-Val-OH 
137 HATU, 4eq, 
60min 
1582 [M+2H]2+ 
1054 [M+3H]3+ 
791 [M+4H]4+- 
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17 Fmoc-Leu-OH 141 HATU, 4eq, 60min 
  
16 Fmoc-Lys(Boc)-OH 188 HATU, 4eq, 60min 
  
15 Fmoc-Gln(Trt)-OH 
244 HATU, 4eq, 
60min 
1769 [M+2H]2+ 
1179 [M+3H]3+ 
884 [M+4H]4+- 
 
14 Fmoc-His(Trt)-OH 248 HATU, 4eq, 60min 
-  
13 Fmoc-His(Trt)-OH 248 HATU, 4eq, 60min 
  
12 Fmoc-Val-OH 200 HATU, 4eq, 60min 
-  
11 Fmoc-Glu(tBu)-OH 
200 HATU, 4eq, 
60min 
1347 [M+3H]3+ 
1010 [M+4H]4+ 
808 [M+5H]5+- 
 
10 Fmoc-Tyr(tBu)-OH 184 HATU, 4eq, 60min 
1051 [M+4H]4+ 
841 [M+5H]5+-- 
 
  9 Fmoc-Gly-OH 119 HATU, 4eq, 60min 
  
8 Fmoc-Ser(tBu)-OH 153 HATU, 4eq, 60min 
-  
7 Fmoc-Asp(tBu)-OH 165 HATU, 4eq, 60min 
-  
6 Fmoc-His(Trt)-OH 248 HATU, 4eq, 60min 
-  
5 Fmoc-Arg(Pbf)-OH 260 HATU, 4eq, 60min 
Maldi-TOF 
4530 [M+H]+ 
small peak in 
maldi 
4 Fmoc-Phe-OH 155 HATU, 4eq, 60min 
-  
3 Fmoc-Glu(tBu)-OH 200 HATU, 4eq, 60min 
-  
2 Fmoc-Ala-OH.H2O 
130 HATU, 4eq, 
60min 
-  
1 Boc-Asp(tBu)-OH 116 HATU, 4eq, 60min 
- - 
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3.7. Synthesis of Amyloid-β  (1-42) derived switch-peptide 23 
H-A!(1-35)-Val-O
H-Orn-Pro-Ser37-A!(38-42)-OH
23 
The synthesis was performed on 1 g of a pre-loaded Fmoc-Ala-NovaSyn TGA resin (loading 
0.20 mmol/g).  
The first Fmoc protecting group was removed with a solution of 20% piperidine in DMF (2x10 
min) and the amino acids Fmoc-Ile-OH and Fmoc-Val-OH was coupled with 2 eq of PyBOP.  
The Fmoc group was then removed with a solution of 2% DBU 5% piperidine in DMF until the 
7th amino acid of the sequence (Aspartic acid) was reached. From 7th to 1st amino acid, Fmoc 
protecting group was removed with 20% piperidine in DMF to avoid aspartimide formation that 
can occur when strong basic conditions are used to remove Fmoc. 
HATU was used as coupling reagent all along the synthesis (2 eq or 4 eq). 
Switch element S at Ser37 was constructed by first coupling Fmoc-Ser-OH without side chain 
protection followed by normal coupling of Fmoc-Pro-OH and Boc-Orn(Boc)-OH. Fmoc-Val36-
OH was then coupled via an ester bond to the free side chain of the serine with DIC 3eq and 
DMAP 0.5 eq. 
To facilitate the synthesis on the resin the pseudo-proline building block Fmoc-Gly25-
Ser26(ψMe,Me)pro-OH was used. During the final cleavage, the pseudo-proline opened and the 
normal sequence was restored. 
Cleavage test assays were performed during the synthesis and analyzed by HPLC, ESI-MS or 
MALDI-TOF to check the correct evolution of the synthesis. 
 
Residue Quantity (mg) 
Coupling 
conditions Cleavage test remarks 
41 Fmoc-Ile-OH 
176 PyBOP, 2.5eq,  
2 x 20min 
- 20% piperidine 
40 Fmoc-Val-OH 170 PyBOP, 2.5eq,  2 x 20min 
525 [M+H]+-  
39 Fmoc-Val-OH 170 HATU, 2.5eq,  2 x 20min 
-  
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38 Fmoc-Gly-OH 150 HATU, 2.5eq,  2 x 20min 
-  
37 Fmoc-Ser(OH)-OH 164 PyBOP, 2.5eq,  2 x2 0min 
-  
Fmoc-Pro-OH.H2O 
169 PyBOP, 2.5eq,  
2 x 20min 
  
Boc-Orn(Boc)-OH 166 PyBOP, 2.5eq,  2 x 20min 
Rt = 13.1 min 
756 [M+H]+ 
- 
36 Fmoc-Val-OH 
170 CDI, 3eq, 
2x120min 
Rt = 21.4 min 
1077 [M+H]+ 
 
 
35 Fmoc-Met-OH 186 HATU, 2.5eq,  2 x 20min 
-  
34 Fmoc-Leu-OH 176 HATU, 2.5eq,  2 x 20min 
  
33 Fmoc-Gly-OH 150 HATU, 2.5eq,  2 x 20min 
-  
32 Fmoc-Ile-OH 176 HATU, 2.5eq,  2 x 20min 
1606 [M+H]+ 
803 [M+2H]2+- 
 
31 Fmoc-Ile-OH 176 HATU, 2.5eq,  2 x 20min 
-  
30 Fmoc-Ala-OH.H2O 
164 HATU, 2.5eq,  
2 x 20min 
-  
29 Fmoc-Gly-OH 150 HATU, 2.5eq,  2 x 20min 
-  
28 Fmoc-Lys(Boc)-OH 235 HATU, 2.5eq,  2 x 20min 
-  
27 Fmoc-Asn(Trt)-OH 300 HATU, 2.5eq,  2 x 20min 
  
25-26 Fmoc-Gly25-
Ser26(ψMe,Me)pro-OH 
212 HATU, 2.5eq, 2 x 
40min 
Rt = 16.9 min 
1059 [M+2H]2+ 
706 [M+3H]3+ 
- 
     
24 Fmoc-Val-OH 170 HATU, 2.5eq,  2 x 20min 
-  
23 Fmoc-Asp(tBu)-OH 205 HATU, 2.5eq,  2 x 20min 
  
22 Fmoc-Glu(tBu)-OH 221 HATU, 2.5eq,  2 x 20min 
-  
21 Fmoc-Ala-OH.H2O 
164 HATU, 2.5eq,  
2 x 20min 
-  
20 Fmoc-Phe-OH 
194 HATU, 2.5eq,  
2 x 20min 
1339 [M+2H]2+ 
893 [M+3H]3+ 
669 [M+4H]4+ 
 
19 Fmoc-Phe-OH 194 HATU, 2.5eq,  2 x 20min 
-  
18 Fmoc-Val-OH 170 HATU, 2.5eq, 2 x 20min 
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17 Fmoc-Leu-OH 176 HATU, 2.5eq,  2 x 20min 
  
16 Fmoc-Lys(Boc)-OH 235 HATU, 2.5eq,  2 x 20min 
  
15 Fmoc-Gln(Trt)-OH 
305 HATU, 2.5eq,  
2 x 20min 
1647 [M+2H]2+ 
1098 [M+3H]3+ 
823 [M+4H]4+- 
 
14 Fmoc-His(Trt)-OH 310 HATU, 2.5eq,  2 x 20min 
-  
13 Fmoc-His(Trt)-OH 310 HATU, 2.5eq,  2 x 20min 
  
12 Fmoc-Val-OH 170 HATU, 2.5eq,  2 x 20min 
-  
11 Fmoc-Glu(tBu)-OH 221 HATU, 2.5eq,  2 x 20min 
  
10 Fmoc-Tyr(tBu)-OH 230 HATU, 2.5eq,  2 x 20min 
--  
9 Fmoc-Gly-OH 
150 HATU, 2.5eq,  
2 x 20min 
1339 [M+3H]3+ 
1004 [M+4H]4+- 
803 [M+5H]5+ 
 
8 Fmoc-Ser(tBu)-OH 192 HATU, 2.5eq,  2 x 20min 
-  
7 Fmoc-Asp(tBu)-OH 
205 HATU, 2.5eq, 
60min 
- Deprotection 
with 20% 
piperidine 
6 Fmoc-His(Trt)-OH 310 HATU, 2.5eq,  2 x 20min 
-  
5 Fmoc-Arg(Pbf)-OH 324 HATU, 2.5eq,  2 x 20min 
 small signal in 
ESI/MS 
4 Fmoc-Phe-OH 194 HATU, 2.5eq,  2 x 20min 
-  
3 Fmoc-Glu(tBu)-OH 221 HATU, 2.5eq,  2 x 20min 
-  
2 Fmoc-Ala-OH.H2O 
164 HATU, 2.5eq,  
2 x 20min 
-  
1 Boc-Asp(tBu)-OH 
145 HATU, 2.5eq, 
2 x 20min 
1584 [M+3H]3+ 
1188 [M+4H]4+- 
905 [M+5H]5+- 
- 
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Product Index 
 Fmoc
NH
O
O
H
N
OBzl
O
Boc
 
Fmoc-Leu-(Boc)Ser-OBzl 1 
Fmoc
NH
O
O
H
N
OH
O
Boc
 
Fmoc-Leu-(Boc)Ser-OH 2 
OH
H
N
OBzl
O
O
O
O
O NO2
 
NVOC-Ser-OBzl 3 
O
H
N
OBzl
O
O
O
O
O NO2
O
NH
Fmoc  
Fmoc-Gly-(NVOC)Ser-OBzl 4 
Product Index 
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O
H
N
OH
O
O
O
O
O NO2
O
NH
Fmoc  
Fmoc-Gly-(NVOC)Ser-OH 5 
OH
H
N
OH
O
O
N
H
Fmoc
 
Fmoc-Gly-(NVOC)Ser-OH 6 
Ac-Lys-Ala-Arg-Ala-Asp-Ala-O
H-Ser-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-NH2
 
7 
H-Arg-Pro-Ser-Glu-Asp-Val24-Ser-Leu-Gly-NH2
Ac-Ser-Leu-Ser-Leu-14His-Gln-Lys-Leu-Val-Phe-Phe-O  
8 
Ac-Ser-Leu-O
H-Ser-Leu-14His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val24-O
H-Ser-Leu-Gly-NH2
 
9 
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HN
S
O
OH
 
H-Cys(ΨMe,Mepro)-OH 10 
HN
S
O
OH
 
H-Cys(ΨH, Hpro)-OH 11 
N
H
O
F
O  
Ac-Leu-F 12 
N
H
O
N
S
O
O
OH
 
Ac-Leu-Cys(ΨMe,Mepro)-OH 13 
N
H
O
N
S
O
O
OH
 
Ac-Leu-Cys(ΨH, Hpro)-OH 14 
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H - Ser -  Phe - Phe - Asp -  NH2
Ac - Leu - Cys(!Me, Mepro) -Ala-O  
15 
H - Ser -  Phe - Phe - Asp -  NH2
Ac - Leu - Cys(!H, Hpro) -Ala-O  
16 
H - Ser -  (NMe)Phe - Phe - Asp -  NH2
Ac - Leu - Cys(!Me, Mepro) -Ala-O  
17 
H - Ser -  (NMe)Phe - Phe - Asp -  NH2
Ac - Leu - Cys(!H, Hpro) -Ala-O  
18 
H-Arg-Pro- Ser -  (NMe)Phe - Phe - Asp -  NH2
Ac - Leu - Cys(!Me, Mepro) -Ala-O  
19 
H-A!(1-24)-Gly-O
H-Lys-Pro-Ser-A!(27-42)-OH
 
20 
H-A!(1-24)-Gly-O
H-Ser26-A!(27-35)-Val-O
H-Orn-Pro-Ser37-A!(38-42)-OH
 
21 
Product Index 
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H-A!(1-24)-Gly-O
NVOC-Ser26-A!(27-35)-Val-O
H-Orn-Pro-Ser37-A!(38-42)-OH
 
22 
H-A!(1-35)-Val-O
H-Orn-Pro-Ser37-A!(38-42)-OH
 
23 
OHO
OH O
OH
OH
OH
OH
 
Myricetin 
NH2
OH
HO
 
Dopamine 
O
O
NH2  
Dopaquinone (oxidized dopamine) 
Product Index 
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